<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="add16659" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Addiction</journal-id><journal-id journal-id-type="iso-abbrev">Addiction</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">ADD</journal-id><journal-title-group><journal-title>Addiction (Abingdon, England)</journal-title></journal-title-group><issn pub-type="ppub">0965-2140</issn><issn pub-type="epub">1360-0443</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11638524</article-id><article-id pub-id-type="pmcid-ver">PMC11638524.1</article-id><article-id pub-id-type="pmcaid">11638524</article-id><article-id pub-id-type="pmcaiid">11638524</article-id><article-id pub-id-type="pmid">39243190</article-id><article-id pub-id-type="doi">10.1111/add.16659</article-id><article-id pub-id-type="publisher-id">ADD16659</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Report</subject></subj-group></article-categories><title-group><article-title>Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type</article-title><alt-title alt-title-type="right-running-head">Medications for opioid use disorder</alt-title><alt-title alt-title-type="left-running-head">Hayes et al.</alt-title></title-group><contrib-group><contrib id="add16659-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Hayes</surname><given-names initials="CJ">Corey J.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7776-6157</contrib-id><xref rid="add16659-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="add16659-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="add16659-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>cjhayes@uams.edu</email></address></contrib><contrib id="add16659-cr-0002" contrib-type="author"><name name-style="western"><surname>Raciborski</surname><given-names initials="RA">Rebecca A.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4135-9074</contrib-id><xref rid="add16659-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="add16659-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="add16659-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="add16659-cr-0003" contrib-type="author"><name name-style="western"><surname>Nowak</surname><given-names initials="M">Matthew</given-names></name><xref rid="add16659-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="add16659-cr-0004" contrib-type="author"><name name-style="western"><surname>Acharya</surname><given-names initials="M">Mahip</given-names></name><xref rid="add16659-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="add16659-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="add16659-cr-0005" contrib-type="author"><name name-style="western"><surname>Nunes</surname><given-names initials="EV">Edward V.</given-names><suffix>Jr</suffix></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2055-3425</contrib-id><xref rid="add16659-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="add16659-cr-0006" contrib-type="author"><name name-style="western"><surname>Winhusen</surname><given-names initials="TJ">T. John</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3364-0739</contrib-id><xref rid="add16659-aff-0009" ref-type="aff">
<sup>9</sup>
</xref><xref rid="add16659-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib></contrib-group><aff id="add16659-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Biomedical Informatics, College of Medicine</named-content>
<institution>University of Arkansas for Medical Sciences</institution>
<city>Little Rock</city>
<named-content content-type="country-part">AR</named-content>
<country country="US">USA</country>
</aff><aff id="add16659-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Institute for Digital Health and Innovation, College of Medicine</named-content>
<institution>University of Arkansas for Medical Sciences</institution>
<city>Little Rock</city>
<named-content content-type="country-part">AR</named-content>
<country country="US">USA</country>
</aff><aff id="add16659-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Center for Mental Healthcare and Outcomes Research</named-content>
<institution>Central Arkansas Veterans Healthcare System</institution>
<city>North Little Rock</city>
<named-content content-type="country-part">AR</named-content>
<country country="US">USA</country>
</aff><aff id="add16659-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Behavioral Health Quality Enhancement Research Initiative</named-content>
<institution>Central Arkansas Veterans Healthcare System</institution>
<city>North Little Rock</city>
<named-content content-type="country-part">AR</named-content>
<country country="US">USA</country>
</aff><aff id="add16659-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Evidence, Policy, and Implementation Center</named-content>
<institution>Central Arkansas Veterans Healthcare System</institution>
<city>North Little Rock</city>
<named-content content-type="country-part">AR</named-content>
<country country="US">USA</country>
</aff><aff id="add16659-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">College of Medicine</named-content>
<institution>University of Arkansas for Medical Sciences</institution>
<city>Little Rock</city>
<named-content content-type="country-part">AR</named-content>
<country country="US">USA</country>
</aff><aff id="add16659-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Department of Obstetrics and Gynecology, College of Medicine</named-content>
<institution>University of Arkansas for Medical Sciences</institution>
<city>Little Rock</city>
<named-content content-type="country-part">AR</named-content>
<country country="US">USA</country>
</aff><aff id="add16659-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Division of Substance Use Disorders, Department of Psychiatry</named-content>
<institution>Columbia University Irving Medical Center</institution>
<city>New York</city>
<named-content content-type="country-part">NY</named-content>
<country country="US">USA</country>
</aff><aff id="add16659-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Department of Psychiatry and Behavioral Neuroscience</named-content>
<institution>University of Cincinnati College of Medicine</institution>
<city>Cincinnati</city>
<named-content content-type="country-part">OH</named-content>
<country country="US">USA</country>
</aff><aff id="add16659-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Center for Addiction Research</named-content>
<institution>University of Cincinnati College of Medicine</institution>
<city>Cincinnati</city>
<named-content content-type="country-part">OH</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Corey J. Hayes, Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Healthcare System, 4301 W. Markham Street, Slot 782, North Little Rock, AR, 72205, USA.<break/>
Email: <email>cjhayes@uams.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2025</year></pub-date><volume>120</volume><issue seq="160">1</issue><issue-id pub-id-type="pmc-issue-id">476986</issue-id><issue-id pub-id-type="doi">10.1111/add.v120.1</issue-id><fpage>138</fpage><lpage>151</lpage><history><date date-type="received"><day>19</day><month>2</month><year>2024</year></date><date date-type="accepted"><day>30</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>13</day><month>12</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>14</day><month>12</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-17 15:25:14.450"><day>17</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2024 The Author(s). <italic toggle="yes">Addiction</italic> published by John Wiley &amp; Sons Ltd on behalf of Society for the Study of Addiction.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ADD-120-138.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ADD-120-138.pdf"/><abstract><title>Abstract</title><sec id="add16659-sec-0001"><title>Aim</title><p>This study: (1) estimated the effect of early discontinuation of medication for opioid use disorder (MOUD) on overdose probability and (2) measured the relationship between patient characteristics and early discontinuation probability for each MOUD type.</p></sec><sec id="add16659-sec-0002"><title>Design, setting and participants</title><p>This was a retrospective cohort using electronic health record data from the US Veterans Healthcare Administration. Participants were veterans initiating MOUD with buprenorphine (BUP), methadone (MET) or extended&#8208;release naltrexone (XR&#8208;NTX) from fiscal years 2012&#8211;19. A total of 39&#8201;284 veterans met eligibility with 22&#8201;721 (57.8%) initiating BUP, 12&#8201;652 (32.2%) initiating MET and 3911 (10.0%) initiating XR&#8208;NTX.</p></sec><sec id="add16659-sec-0003"><title>Measurements</title><p>Measurements (1) determined whether the veteran experienced an overdose in the 365&#8201;days after MOUD initiation (primary) and (2) early discontinuation of MOUD, defined as discontinuation before 180&#8201;days (secondary). We assumed that unobserved patient characteristics would jointly influence the probability of discontinuation and overdose. and estimated the joint distribution with a bivariate probit model.</p></sec><sec id="add16659-sec-0004"><title>Findings</title><p>We found that 9.0% of BUP initiators who experienced an overdose above the predicted 3.9% had no veteran&#8208;discontinued BUP early; findings for XR&#8208;NTX were similar, with 12.2% of initiators overdosing above the predicted 4.5%, but this was statistically inconclusive. We found no relationship between early discontinuation and overdose for MET initiators, probably due to the high risk of both events. The patient characteristics included in our post&#8208;estimation exploratory analysis of early discontinuation varied by MOUD type, with between 14 (XR&#8208;NTX) and 25 (BUP) tested. The only characteristics with at least one level showing a statistically significant change in probability of early discontinuation for all three MOUD types were geography and prior&#8208;year exposure to psychotherapy, although direction and magnitude varied.</p></sec><sec id="add16659-sec-0005"><title>Conclusion</title><p>Early discontinuation of buprenorphine, and probably extended&#8208;release naltrexone, appears to be associated with a greater probability of experiencing a fatal or non&#8208;fatal overdose among US veterans receiving medication for opioid use disorder (MOUD); methadone does not show the same association. There is no consistent set of characteristics among early discontinuers by MOUD type.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="add16659-kwd-0001">Geographic disparities</kwd><kwd id="add16659-kwd-0002">medication treatment for opioid use disorder</kwd><kwd id="add16659-kwd-0003">opioid use disorder</kwd><kwd id="add16659-kwd-0004">overdose</kwd><kwd id="add16659-kwd-0005">racial disparities</kwd><kwd id="add16659-kwd-0006">veterans</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Institute on Drug Abuse of the National Institutes of Health
</institution><institution-id institution-id-type="doi">10.13039/100015615</institution-id></institution-wrap></funding-source><award-id>UG1DA013732&#8208;23S3</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>VA Health Services Research
</institution><institution-id institution-id-type="doi">10.13039/100007217</institution-id></institution-wrap></funding-source><award-id>IK2HX003358</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="14"/><word-count count="9900"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:13.12.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="add16659-cit-9001"><string-name name-style="western"><surname>Hayes</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Raciborski</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Nowak</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Acharya</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nunes</surname><given-names>EV</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Winhusen</surname><given-names>TJ</given-names></string-name>. <article-title>Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type</article-title>. <source>Addiction</source>. <year>2025</year>;<volume>120</volume>(<issue>1</issue>):<fpage>138</fpage>&#8211;<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1111/add.16659</pub-id><pub-id pub-id-type="pmcid">PMC11638524</pub-id><pub-id pub-id-type="pmid">39243190</pub-id></mixed-citation>
</p></notes></front><body id="add16659-body-0001"><sec id="add16659-sec-0006"><title>INTRODUCTION</title><p>The opioid crisis is one of the most important public health emergencies of our time [<xref rid="add16659-bib-0001" ref-type="bibr">1</xref>, <xref rid="add16659-bib-0002" ref-type="bibr">2</xref>, <xref rid="add16659-bib-0003" ref-type="bibr">3</xref>]. In the decade following 2010 overdose deaths in the United States increased nearly fourfold, with opioid overdoses accounting for three&#8208;quarters of these deaths [<xref rid="add16659-bib-0003" ref-type="bibr">3</xref>, <xref rid="add16659-bib-0004" ref-type="bibr">4</xref>]. Among US military veterans, drug overdose mortality rates increased 53% from 2010 to 2019 [<xref rid="add16659-bib-0005" ref-type="bibr">5</xref>]. Medication for opioid use disorder (MOUD) includes maintenance treatment with methadone (MET, a full opioid agonist), buprenorphine (BUP, a partial opioid agonist) and extended&#8208;release naltrexone (XR&#8208;NTX, an opioid antagonist). MOUD is the standard of care because it reduces opioid&#8208;related mortality and morbidity [<xref rid="add16659-bib-0006" ref-type="bibr">6</xref>, <xref rid="add16659-bib-0007" ref-type="bibr">7</xref>, <xref rid="add16659-bib-0008" ref-type="bibr">8</xref>, <xref rid="add16659-bib-0009" ref-type="bibr">9</xref>, <xref rid="add16659-bib-0010" ref-type="bibr">10</xref>, <xref rid="add16659-bib-0011" ref-type="bibr">11</xref>, <xref rid="add16659-bib-0012" ref-type="bibr">12</xref>, <xref rid="add16659-bib-0013" ref-type="bibr">13</xref>]. However, early MOUD discontinuation can have swift and severe consequences for patient health [<xref rid="add16659-bib-0014" ref-type="bibr">14</xref>]; for example, mortality increases sixfold in the 4&#160;weeks following MOUD discontinuation [<xref rid="add16659-bib-0013" ref-type="bibr">13</xref>]. Unfortunately, only 50&#8211;60% of patients remain on MOUD for the recommended minimum of 6&#160;months, a minimum duration of treatment set by the Health Effectiveness Data and Information Set (HEDIS) and National Committee on Quality Assurance [<xref rid="add16659-bib-0015" ref-type="bibr">15</xref>, <xref rid="add16659-bib-0016" ref-type="bibr">16</xref>, <xref rid="add16659-bib-0017" ref-type="bibr">17</xref>, <xref rid="add16659-bib-0018" ref-type="bibr">18</xref>].</p><p>A recent Agency for Healthcare Research and Quality review found no evidence&#8208;based practices for mitigating early MOUD discontinuation for agonist/partial agonist therapy and only some evidence that one intervention (contingency management) may mitigate early MOUD discontinuation for antagonist therapy [<xref rid="add16659-bib-0019" ref-type="bibr">19</xref>]. In addition to developing interventions, a possible approach to mitigating early MOUD discontinuation would be using patient characteristics to select the MOUD with which patients are most likely to be successful. For example, there is some evidence that patients with depression might benefit more from BUP than from MET [<xref rid="add16659-bib-0020" ref-type="bibr">20</xref>]. There is also evidence that individuals who are White or used cocaine at baseline respond better to MET than to BUP [<xref rid="add16659-bib-0021" ref-type="bibr">21</xref>]. Evidence from a recent randomized comparative&#8208;effectiveness trial found that unhoused patients on XR&#8208;NTX have lower discontinuation rates, while patients with permanent shelter had lower discontinuation rates with BUP [<xref rid="add16659-bib-0022" ref-type="bibr">22</xref>]. Secondary analyses of clinical trials have attempted to identify patient characteristics associated with better treatment outcomes (e.g. retention, abstinence); however, clinical trials often exclude conditions prevalent in clinical populations, such as co&#8208;occurring substance use disorders, that may be predictive of treatment outcomes. Therefore, scant evidence exists on which to personalize the selection of the type of MOUD to mitigate early MOUD discontinuation [<xref rid="add16659-bib-0023" ref-type="bibr">23</xref>, <xref rid="add16659-bib-0024" ref-type="bibr">24</xref>, <xref rid="add16659-bib-0025" ref-type="bibr">25</xref>, <xref rid="add16659-bib-0026" ref-type="bibr">26</xref>].</p><p>Each type of MOUD provides differing advantages, disadvantages and challenges that can diminish or enhance its efficacy [<xref rid="add16659-bib-0027" ref-type="bibr">27</xref>]. Qualitative data suggest that a mismatch between MOUD type initiated and patient characteristics or preferences could lead to early discontinuation. For example, withdrawal, the lack of adequate pain control or the ability to have telemedicine appointments have been reasons identified for early discontinuation that vary by MOUD type [<xref rid="add16659-bib-0028" ref-type="bibr">28</xref>]. Clinicians need more information to help minimize the probability of discontinuation and overdose once initiated on a given type of MOUD. However, limited evidence exists regarding how the probability of early MOUD discontinuation could be minimized with greater personalization of MOUD following initiation on a given type of MOUD, which is vital for veterans, given the substantial increase in drug overdose mortality rates over the past decade.</p><p>Using real&#8208;world data from the Veterans Health Administration (VHA), the largest integrated health&#8208;care system and largest OUD treatment provider in the United States [<xref rid="add16659-bib-0029" ref-type="bibr">29</xref>], this study estimates the association between early discontinuation of MOUD and the probability of experiencing a fatal or non&#8208;fatal overdose for each of the three MOUD types: BUP, MET and XR&#8208;NTX. We hypothesized that veterans who discontinued MOUD early would have a higher probability of experiencing a fatal or non&#8208;fatal overdose compared to those who were retained on treatment for at least 180&#8201;days among all MOUD types; however, we also hypothesized that the magnitude of the probability would differ by MOUD type, as early discontinuation rates have been shown recently to differ by MOUD type [<xref rid="add16659-bib-0030" ref-type="bibr">30</xref>]. In an exploratory analysis, we also sought to quantify the association between patient characteristics and the probability of early discontinuation by MOUD type to support future MOUD personalization efforts.</p></sec><sec sec-type="methods" id="add16659-sec-0007"><title>METHODS</title><sec id="add16659-sec-0008"><title>Study design and data sources</title><p>This study was a National Drug Abuse Treatment Clinical Trials Network study (CTN&#8208;0142) [<xref rid="add16659-bib-0031" ref-type="bibr">31</xref>, <xref rid="add16659-bib-0032" ref-type="bibr">32</xref>]. The analysis plan was pre&#8208;specified and is available at the National Drug Abuse Treatment Clinical Trials Network Dissemination Library. CTN&#8208;0142 had two objectives; this paper reports on the findings from the first objective.</p><p>This retrospective cohort study used VHA's Corporate Data Warehouse (CDW) linked with the VHA/DoD Mortality Data Repository [<xref rid="add16659-bib-0033" ref-type="bibr">33</xref>]. The primary (distal) outcome was overdose within 1&#8201;year of MOUD initiation. The exposure of interest was discontinuation of MOUD before completing 180&#8201;days of therapy (&#8216;early discontinuation&#8217;). The exposure was also treated as a secondary (proximal) outcome of interest, as we sought to explore patient factors associated with early discontinuation. The analysis plan was pre&#8208;specified and is available at the National Drug Abuse Treatment Clinical Trials Network Dissemination Library (CTN&#8208;0142) [<xref rid="add16659-bib-0031" ref-type="bibr">31</xref>, <xref rid="add16659-bib-0032" ref-type="bibr">32</xref>]. However, as the analysis plan was not pre&#8208;registered, the results should be considered exploratory.</p><p>The CDW contains a wide range of abstracted electronic health record (EHR) data, together with detailed personal data collected at the time the veteran enrolled in VHA, during eligibility assessment or review, and demographic information collected or confirmed during health&#8208;care encounters. The CDW also contains treating facility and provider characteristics from VHA administrative data. In addition to linking with the Mortality Data Repository, we linked veteran ZIP codes to Rural&#8211;Urban Commuting Area (RUCA) codes&#160;[<xref rid="add16659-bib-0034" ref-type="bibr">34</xref>] and linked veteran county to the Social Vulnerability Index (SVI) from the US Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry (CDC/ATSDR) [<xref rid="add16659-bib-0035" ref-type="bibr">35</xref>, <xref rid="add16659-bib-0036" ref-type="bibr">36</xref>].</p><p>The study was approved by the Central Arkansas Veterans Healthcare System Institutional Review Board. We report results using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [<xref rid="add16659-bib-0037" ref-type="bibr">37</xref>].</p></sec><sec id="add16659-sec-0009"><title>Study population and cohort identification</title><p>The study was set in all VHA facilities that were operational in the United States at any time during the study, providing geographic representation for all 50 States. We screened all VHA&#8208;enrolled US military veterans diagnosed with OUD between 1&#8201;October 2011 and 30&#8201;September 2019 (fiscal years 2012&#8211;19) who also received any form of MOUD. OUD diagnosis was operationalized following a previously published algorithm&#160;[<xref rid="add16659-bib-0038" ref-type="bibr">38</xref>]. When confirming eligibility, we restricted prescription or dispensation records only to initiations of BUP, MET or XR&#8208;NTX, where initiation was defined as the start of a treatment episode with no exposure to MOUD in the 6&#160;months prior to the fill or administration date. We adopted the date of MOUD initiation as the index date. Diagnosis codes for OUD and details on the creation of initiation episodes can be found in the Supporting information, Table&#160;<xref rid="add16659-supitem-0001" ref-type="supplementary-material">S1</xref>.</p><p>To be eligible for the study, veterans had to (a) have a MOUD prescription or administration record after an OUD diagnosis within the study period [<xref rid="add16659-bib-0039" ref-type="bibr">39</xref>, <xref rid="add16659-bib-0040" ref-type="bibr">40</xref>, <xref rid="add16659-bib-0041" ref-type="bibr">41</xref>], (b) be aged 18&#8201;years or older at initiation and (c) reside in the United States. We excluded veterans (a) for whom we could not determine the date when enrollment was completed, (b) who were not regular users of VHA or (c) who received MOUD from a non&#8208;VHA source. We made additional exclusions of otherwise eligible veterans if the index date did not permit a full 365&#8201;days of historical observation and follow&#8208;up. The processes for data checking and manipulation are described in the Supporting <xref rid="add16659-supitem-0001" ref-type="supplementary-material">information</xref>.</p><p>We defined three cohorts based on the type of treatment initiated. We used a previously validated VHA&#8208;specific algorithm to identify the type of MOUD used from a variety of record types [<xref rid="add16659-bib-0039" ref-type="bibr">39</xref>]. Our final analytical sample was 22&#8201;721 BUP initiators, 12&#8201;652 MET initiators and 3911 XR&#8208;NTX initiators (Supporting information, Figure&#160;<xref rid="add16659-supitem-0002" ref-type="supplementary-material">S1</xref>). Table&#160;<xref rid="add16659-tbl-0001" ref-type="table">1</xref> provides sample characteristics for each cohort. Because all analyses are within cohort, we did not test for statistical differences in sample characteristics across cohorts.</p><table-wrap position="float" id="add16659-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Characteristics of veterans, providers and facilities by type of MOUD initiated.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr><th rowspan="2" align="left" valign="bottom" colspan="1"/><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1"/><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">Type of MOUD initiated</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1"/></tr><tr style="border-bottom:solid 1px #000000"><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">BUP</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">MET</th><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">XR&#8208;NTX</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#8201;=&#8201;39&#160;284</td><td colspan="2" align="left" valign="top" rowspan="1">
<italic toggle="yes">n</italic>&#8201;=&#8201;22&#160;721</td><td colspan="2" align="left" valign="top" rowspan="1">
<italic toggle="yes">n</italic>&#8201;=&#8201;12&#160;652</td><td colspan="2" align="left" valign="top" rowspan="1">
<italic toggle="yes">n</italic>&#8201;=&#8201;3911</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Discontinued MOUD before 180&#8201;days (<italic toggle="yes">n</italic>, %)</td><td align="left" valign="top" rowspan="1" colspan="1">11&#8201;464</td><td align="left" valign="top" rowspan="1" colspan="1">(50.5)</td><td align="left" valign="top" rowspan="1" colspan="1">10&#8201;721</td><td align="left" valign="top" rowspan="1" colspan="1">(84.7)</td><td align="left" valign="top" rowspan="1" colspan="1">3343</td><td align="left" valign="top" rowspan="1" colspan="1">(85.5)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Overdose in the year after initiation (<italic toggle="yes">n</italic>, %)</td><td align="left" valign="top" rowspan="1" colspan="1">2036</td><td align="left" valign="top" rowspan="1" colspan="1">(9.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1007</td><td align="left" valign="top" rowspan="1" colspan="1">(8.0)</td><td align="left" valign="top" rowspan="1" colspan="1">477</td><td align="left" valign="top" rowspan="1" colspan="1">(12.2)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">MOUD fiscal year (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2012</td><td align="left" valign="top" rowspan="1" colspan="1">2311</td><td align="left" valign="top" rowspan="1" colspan="1">(10.2)</td><td align="left" valign="top" rowspan="1" colspan="1">1877</td><td align="left" valign="top" rowspan="1" colspan="1">(14.8)</td><td align="left" valign="top" rowspan="1" colspan="1">78</td><td align="left" valign="top" rowspan="1" colspan="1">(2.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2013</td><td align="left" valign="top" rowspan="1" colspan="1">2480</td><td align="left" valign="top" rowspan="1" colspan="1">(10.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1682</td><td align="left" valign="top" rowspan="1" colspan="1">(13.3)</td><td align="left" valign="top" rowspan="1" colspan="1">118</td><td align="left" valign="top" rowspan="1" colspan="1">(3.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2014</td><td align="left" valign="top" rowspan="1" colspan="1">2503</td><td align="left" valign="top" rowspan="1" colspan="1">(11.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1511</td><td align="left" valign="top" rowspan="1" colspan="1">(11.9)</td><td align="left" valign="top" rowspan="1" colspan="1">165</td><td align="left" valign="top" rowspan="1" colspan="1">(4.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2015</td><td align="left" valign="top" rowspan="1" colspan="1">2698</td><td align="left" valign="top" rowspan="1" colspan="1">(11.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1533</td><td align="left" valign="top" rowspan="1" colspan="1">(12.1)</td><td align="left" valign="top" rowspan="1" colspan="1">356</td><td align="left" valign="top" rowspan="1" colspan="1">(9.1)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2016</td><td align="left" valign="top" rowspan="1" colspan="1">2841</td><td align="left" valign="top" rowspan="1" colspan="1">(12.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1947</td><td align="left" valign="top" rowspan="1" colspan="1">(15.4)</td><td align="left" valign="top" rowspan="1" colspan="1">599</td><td align="left" valign="top" rowspan="1" colspan="1">(15.3)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2017</td><td align="left" valign="top" rowspan="1" colspan="1">2915</td><td align="left" valign="top" rowspan="1" colspan="1">(12.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1488</td><td align="left" valign="top" rowspan="1" colspan="1">(11.8)</td><td align="left" valign="top" rowspan="1" colspan="1">780</td><td align="left" valign="top" rowspan="1" colspan="1">(19.9)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2018</td><td align="left" valign="top" rowspan="1" colspan="1">3215</td><td align="left" valign="top" rowspan="1" colspan="1">(14.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1396</td><td align="left" valign="top" rowspan="1" colspan="1">(11.0)</td><td align="left" valign="top" rowspan="1" colspan="1">958</td><td align="left" valign="top" rowspan="1" colspan="1">(24.5)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2019</td><td align="left" valign="top" rowspan="1" colspan="1">3758</td><td align="left" valign="top" rowspan="1" colspan="1">(16.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1218</td><td align="left" valign="top" rowspan="1" colspan="1">(9.6)</td><td align="left" valign="top" rowspan="1" colspan="1">857</td><td align="left" valign="top" rowspan="1" colspan="1">(21.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years; mean, SD)</td><td align="left" valign="top" rowspan="1" colspan="1">46.09</td><td align="left" valign="top" rowspan="1" colspan="1">(14.46)</td><td align="left" valign="top" rowspan="1" colspan="1">50.86</td><td align="left" valign="top" rowspan="1" colspan="1">(13.96)</td><td align="left" valign="top" rowspan="1" colspan="1">46.45</td><td align="left" valign="top" rowspan="1" colspan="1">(13.07)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Sex (<italic toggle="yes">n</italic>, %)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="left" valign="top" rowspan="1" colspan="1">20&#8201;921</td><td align="left" valign="top" rowspan="1" colspan="1">(92.1)</td><td align="left" valign="top" rowspan="1" colspan="1">11&#8201;815</td><td align="left" valign="top" rowspan="1" colspan="1">(93.4)</td><td align="left" valign="top" rowspan="1" colspan="1">3615</td><td align="left" valign="top" rowspan="1" colspan="1">(92.4)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Self&#8208;identified race (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">American Indian or Alaska Native</td><td align="left" valign="top" rowspan="1" colspan="1">164</td><td align="left" valign="top" rowspan="1" colspan="1">(0.7)</td><td align="left" valign="top" rowspan="1" colspan="1">102</td><td align="left" valign="top" rowspan="1" colspan="1">(0.8)</td><td align="left" valign="top" rowspan="1" colspan="1">45</td><td align="left" valign="top" rowspan="1" colspan="1">(1.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Asian</td><td align="left" valign="top" rowspan="1" colspan="1">67</td><td align="left" valign="top" rowspan="1" colspan="1">(0.3)</td><td align="left" valign="top" rowspan="1" colspan="1">45</td><td align="left" valign="top" rowspan="1" colspan="1">(0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">(0.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Black or African American</td><td align="left" valign="top" rowspan="1" colspan="1">2680</td><td align="left" valign="top" rowspan="1" colspan="1">(11.8)</td><td align="left" valign="top" rowspan="1" colspan="1">3874</td><td align="left" valign="top" rowspan="1" colspan="1">(30.6)</td><td align="left" valign="top" rowspan="1" colspan="1">626</td><td align="left" valign="top" rowspan="1" colspan="1">(16.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Native Hawaiian or Other Pacific Islander</td><td align="left" valign="top" rowspan="1" colspan="1">124</td><td align="left" valign="top" rowspan="1" colspan="1">(0.5)</td><td align="left" valign="top" rowspan="1" colspan="1">60</td><td align="left" valign="top" rowspan="1" colspan="1">(0.5)</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">(0.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White</td><td align="left" valign="top" rowspan="1" colspan="1">18&#8201;332</td><td align="left" valign="top" rowspan="1" colspan="1">(80.7)</td><td align="left" valign="top" rowspan="1" colspan="1">7857</td><td align="left" valign="top" rowspan="1" colspan="1">(62.1)</td><td align="left" valign="top" rowspan="1" colspan="1">3030</td><td align="left" valign="top" rowspan="1" colspan="1">(77.5)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">More than one race</td><td align="left" valign="top" rowspan="1" colspan="1">195</td><td align="left" valign="top" rowspan="1" colspan="1">(0.9)</td><td align="left" valign="top" rowspan="1" colspan="1">129</td><td align="left" valign="top" rowspan="1" colspan="1">(1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">33</td><td align="left" valign="top" rowspan="1" colspan="1">(0.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Declined to answer</td><td align="left" valign="top" rowspan="1" colspan="1">812</td><td align="left" valign="top" rowspan="1" colspan="1">(3.6)</td><td align="left" valign="top" rowspan="1" colspan="1">373</td><td align="left" valign="top" rowspan="1" colspan="1">(2.9)</td><td align="left" valign="top" rowspan="1" colspan="1">108</td><td align="left" valign="top" rowspan="1" colspan="1">(2.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Unknown by patient</td><td align="left" valign="top" rowspan="1" colspan="1">233</td><td align="left" valign="top" rowspan="1" colspan="1">(1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">136</td><td align="left" valign="top" rowspan="1" colspan="1">(1.1)</td><td align="left" valign="top" rowspan="1" colspan="1">36</td><td align="left" valign="top" rowspan="1" colspan="1">(0.9)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Not recorded</td><td align="left" valign="top" rowspan="1" colspan="1">114</td><td align="left" valign="top" rowspan="1" colspan="1">(0.5)</td><td align="left" valign="top" rowspan="1" colspan="1">76</td><td align="left" valign="top" rowspan="1" colspan="1">(0.6)</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">(0.3)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Self&#8208;identified ethnicity (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hispanic or Latino</td><td align="left" valign="top" rowspan="1" colspan="1">1130</td><td align="left" valign="top" rowspan="1" colspan="1">(5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">732</td><td align="left" valign="top" rowspan="1" colspan="1">(5.8)</td><td align="left" valign="top" rowspan="1" colspan="1">197</td><td align="left" valign="top" rowspan="1" colspan="1">(5.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Not Hispanic or Latino</td><td align="left" valign="top" rowspan="1" colspan="1">20&#8201;744</td><td align="left" valign="top" rowspan="1" colspan="1">(91.3)</td><td align="left" valign="top" rowspan="1" colspan="1">11&#8201;483</td><td align="left" valign="top" rowspan="1" colspan="1">(90.8)</td><td align="left" valign="top" rowspan="1" colspan="1">3590</td><td align="left" valign="top" rowspan="1" colspan="1">(91.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Declined to answer</td><td align="left" valign="top" rowspan="1" colspan="1">526</td><td align="left" valign="top" rowspan="1" colspan="1">(2.3)</td><td align="left" valign="top" rowspan="1" colspan="1">253</td><td align="left" valign="top" rowspan="1" colspan="1">(2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">77</td><td align="left" valign="top" rowspan="1" colspan="1">(2.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Unknown by patient</td><td align="left" valign="top" rowspan="1" colspan="1">297</td><td align="left" valign="top" rowspan="1" colspan="1">(1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">162</td><td align="left" valign="top" rowspan="1" colspan="1">(1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">44</td><td align="left" valign="top" rowspan="1" colspan="1">(1.1)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Not recorded</td><td align="left" valign="top" rowspan="1" colspan="1">24</td><td align="left" valign="top" rowspan="1" colspan="1">(0.1)</td><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="left" valign="top" rowspan="1" colspan="1">(0.2)</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">(0.1)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Marital status (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Never married</td><td align="left" valign="top" rowspan="1" colspan="1">5693</td><td align="left" valign="top" rowspan="1" colspan="1">(25.1)</td><td align="left" valign="top" rowspan="1" colspan="1">3439</td><td align="left" valign="top" rowspan="1" colspan="1">(27.2)</td><td align="left" valign="top" rowspan="1" colspan="1">1163</td><td align="left" valign="top" rowspan="1" colspan="1">(29.7)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Married</td><td align="left" valign="top" rowspan="1" colspan="1">6873</td><td align="left" valign="top" rowspan="1" colspan="1">(30.2)</td><td align="left" valign="top" rowspan="1" colspan="1">3187</td><td align="left" valign="top" rowspan="1" colspan="1">(25.2)</td><td align="left" valign="top" rowspan="1" colspan="1">900</td><td align="left" valign="top" rowspan="1" colspan="1">(23.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Separated</td><td align="left" valign="top" rowspan="1" colspan="1">1759</td><td align="left" valign="top" rowspan="1" colspan="1">(7.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1142</td><td align="left" valign="top" rowspan="1" colspan="1">(9.0)</td><td align="left" valign="top" rowspan="1" colspan="1">331</td><td align="left" valign="top" rowspan="1" colspan="1">(8.5)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Divorced</td><td align="left" valign="top" rowspan="1" colspan="1">7659</td><td align="left" valign="top" rowspan="1" colspan="1">(33.7)</td><td align="left" valign="top" rowspan="1" colspan="1">4415</td><td align="left" valign="top" rowspan="1" colspan="1">(34.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1416</td><td align="left" valign="top" rowspan="1" colspan="1">(36.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Widowed</td><td align="left" valign="top" rowspan="1" colspan="1">646</td><td align="left" valign="top" rowspan="1" colspan="1">(2.8)</td><td align="left" valign="top" rowspan="1" colspan="1">439</td><td align="left" valign="top" rowspan="1" colspan="1">(3.5)</td><td align="left" valign="top" rowspan="1" colspan="1">87</td><td align="left" valign="top" rowspan="1" colspan="1">(2.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">91</td><td align="left" valign="top" rowspan="1" colspan="1">(0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">30</td><td align="left" valign="top" rowspan="1" colspan="1">(0.2)</td><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="left" valign="top" rowspan="1" colspan="1">(0.4)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Employment status (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Employed for others</td><td align="left" valign="top" rowspan="1" colspan="1">4391</td><td align="left" valign="top" rowspan="1" colspan="1">(19.3)</td><td align="left" valign="top" rowspan="1" colspan="1">2084</td><td align="left" valign="top" rowspan="1" colspan="1">(16.5)</td><td align="left" valign="top" rowspan="1" colspan="1">706</td><td align="left" valign="top" rowspan="1" colspan="1">(18.1)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Self&#8208;employed</td><td align="left" valign="top" rowspan="1" colspan="1">322</td><td align="left" valign="top" rowspan="1" colspan="1">(1.4)</td><td align="left" valign="top" rowspan="1" colspan="1">157</td><td align="left" valign="top" rowspan="1" colspan="1">(1.2)</td><td align="left" valign="top" rowspan="1" colspan="1">37</td><td align="left" valign="top" rowspan="1" colspan="1">(0.9)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Not employed</td><td align="left" valign="top" rowspan="1" colspan="1">14&#8201;545</td><td align="left" valign="top" rowspan="1" colspan="1">(64.0)</td><td align="left" valign="top" rowspan="1" colspan="1">8855</td><td align="left" valign="top" rowspan="1" colspan="1">(70.0)</td><td align="left" valign="top" rowspan="1" colspan="1">2703</td><td align="left" valign="top" rowspan="1" colspan="1">(69.1)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Retired</td><td align="left" valign="top" rowspan="1" colspan="1">1947</td><td align="left" valign="top" rowspan="1" colspan="1">(8.6)</td><td align="left" valign="top" rowspan="1" colspan="1">1037</td><td align="left" valign="top" rowspan="1" colspan="1">(8.2)</td><td align="left" valign="top" rowspan="1" colspan="1">234</td><td align="left" valign="top" rowspan="1" colspan="1">(6.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">1516</td><td align="left" valign="top" rowspan="1" colspan="1">(6.7)</td><td align="left" valign="top" rowspan="1" colspan="1">519</td><td align="left" valign="top" rowspan="1" colspan="1">(4.1)</td><td align="left" valign="top" rowspan="1" colspan="1">231</td><td align="left" valign="top" rowspan="1" colspan="1">(5.9)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Priority group (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">9466</td><td align="left" valign="top" rowspan="1" colspan="1">(41.7)</td><td align="left" valign="top" rowspan="1" colspan="1">4355</td><td align="left" valign="top" rowspan="1" colspan="1">(34.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1800</td><td align="left" valign="top" rowspan="1" colspan="1">(46.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2&#8211;3</td><td align="left" valign="top" rowspan="1" colspan="1">3843</td><td align="left" valign="top" rowspan="1" colspan="1">(16.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1933</td><td align="left" valign="top" rowspan="1" colspan="1">(15.3)</td><td align="left" valign="top" rowspan="1" colspan="1">604</td><td align="left" valign="top" rowspan="1" colspan="1">(15.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">1024</td><td align="left" valign="top" rowspan="1" colspan="1">(4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1041</td><td align="left" valign="top" rowspan="1" colspan="1">(8.2)</td><td align="left" valign="top" rowspan="1" colspan="1">346</td><td align="left" valign="top" rowspan="1" colspan="1">(8.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">6529</td><td align="left" valign="top" rowspan="1" colspan="1">(28.7)</td><td align="left" valign="top" rowspan="1" colspan="1">4367</td><td align="left" valign="top" rowspan="1" colspan="1">(34.5)</td><td align="left" valign="top" rowspan="1" colspan="1">929</td><td align="left" valign="top" rowspan="1" colspan="1">(23.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">501</td><td align="left" valign="top" rowspan="1" colspan="1">(2.2)</td><td align="left" valign="top" rowspan="1" colspan="1">228</td><td align="left" valign="top" rowspan="1" colspan="1">(1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">47</td><td align="left" valign="top" rowspan="1" colspan="1">(1.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">7A and 7C</td><td align="left" valign="top" rowspan="1" colspan="1">311</td><td align="left" valign="top" rowspan="1" colspan="1">(1.4)</td><td align="left" valign="top" rowspan="1" colspan="1">192</td><td align="left" valign="top" rowspan="1" colspan="1">(1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">48</td><td align="left" valign="top" rowspan="1" colspan="1">(1.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">8A&#8211;G</td><td align="left" valign="top" rowspan="1" colspan="1">1047</td><td align="left" valign="top" rowspan="1" colspan="1">(4.6)</td><td align="left" valign="top" rowspan="1" colspan="1">536</td><td align="left" valign="top" rowspan="1" colspan="1">(4.2)</td><td align="left" valign="top" rowspan="1" colspan="1">137</td><td align="left" valign="top" rowspan="1" colspan="1">(3.5)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">US census region residence (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Northeast</td><td align="left" valign="top" rowspan="1" colspan="1">4792</td><td align="left" valign="top" rowspan="1" colspan="1">(21.1)</td><td align="left" valign="top" rowspan="1" colspan="1">2601</td><td align="left" valign="top" rowspan="1" colspan="1">(20.6)</td><td align="left" valign="top" rowspan="1" colspan="1">1290</td><td align="left" valign="top" rowspan="1" colspan="1">(33.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">South</td><td align="left" valign="top" rowspan="1" colspan="1">9040</td><td align="left" valign="top" rowspan="1" colspan="1">(39.8)</td><td align="left" valign="top" rowspan="1" colspan="1">4087</td><td align="left" valign="top" rowspan="1" colspan="1">(32.3)</td><td align="left" valign="top" rowspan="1" colspan="1">1258</td><td align="left" valign="top" rowspan="1" colspan="1">(32.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Midwest</td><td align="left" valign="top" rowspan="1" colspan="1">4033</td><td align="left" valign="top" rowspan="1" colspan="1">(17.8)</td><td align="left" valign="top" rowspan="1" colspan="1">3376</td><td align="left" valign="top" rowspan="1" colspan="1">(26.7)</td><td align="left" valign="top" rowspan="1" colspan="1">804</td><td align="left" valign="top" rowspan="1" colspan="1">(20.6)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">West</td><td align="left" valign="top" rowspan="1" colspan="1">4856</td><td align="left" valign="top" rowspan="1" colspan="1">(21.4)</td><td align="left" valign="top" rowspan="1" colspan="1">2588</td><td align="left" valign="top" rowspan="1" colspan="1">(20.5)</td><td align="left" valign="top" rowspan="1" colspan="1">559</td><td align="left" valign="top" rowspan="1" colspan="1">(14.3)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Residential rurality (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Urban</td><td align="left" valign="top" rowspan="1" colspan="1">18&#8201;854</td><td align="left" valign="top" rowspan="1" colspan="1">(83.0)</td><td align="left" valign="top" rowspan="1" colspan="1">11&#8201;475</td><td align="left" valign="top" rowspan="1" colspan="1">(90.7)</td><td align="left" valign="top" rowspan="1" colspan="1">3394</td><td align="left" valign="top" rowspan="1" colspan="1">(86.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Large rural city/town</td><td align="left" valign="top" rowspan="1" colspan="1">2256</td><td align="left" valign="top" rowspan="1" colspan="1">(9.9)</td><td align="left" valign="top" rowspan="1" colspan="1">744</td><td align="left" valign="top" rowspan="1" colspan="1">(5.9)</td><td align="left" valign="top" rowspan="1" colspan="1">320</td><td align="left" valign="top" rowspan="1" colspan="1">(8.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Isolated small rural town</td><td align="left" valign="top" rowspan="1" colspan="1">1611</td><td align="left" valign="top" rowspan="1" colspan="1">(7.1)</td><td align="left" valign="top" rowspan="1" colspan="1">433</td><td align="left" valign="top" rowspan="1" colspan="1">(3.4)</td><td align="left" valign="top" rowspan="1" colspan="1">197</td><td align="left" valign="top" rowspan="1" colspan="1">(5.0)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">SVI score (mean, SD)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Socio&#8208;economic status</td><td align="left" valign="top" rowspan="1" colspan="1">0.43</td><td align="left" valign="top" rowspan="1" colspan="1">(0.24)</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td><td align="left" valign="top" rowspan="1" colspan="1">(0.23)</td><td align="left" valign="top" rowspan="1" colspan="1">0.40</td><td align="left" valign="top" rowspan="1" colspan="1">(0.24)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Household characteristics</td><td align="left" valign="top" rowspan="1" colspan="1">0.38</td><td align="left" valign="top" rowspan="1" colspan="1">(0.26)</td><td align="left" valign="top" rowspan="1" colspan="1">0.32</td><td align="left" valign="top" rowspan="1" colspan="1">(0.25)</td><td align="left" valign="top" rowspan="1" colspan="1">0.32</td><td align="left" valign="top" rowspan="1" colspan="1">(0.26)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Racial and ethnic minority status</td><td align="left" valign="top" rowspan="1" colspan="1">0.70</td><td align="left" valign="top" rowspan="1" colspan="1">(0.25)</td><td align="left" valign="top" rowspan="1" colspan="1">0.78</td><td align="left" valign="top" rowspan="1" colspan="1">(0.24)</td><td align="left" valign="top" rowspan="1" colspan="1">0.70</td><td align="left" valign="top" rowspan="1" colspan="1">(0.25)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Housing type and transportation</td><td align="left" valign="top" rowspan="1" colspan="1">0.62</td><td align="left" valign="top" rowspan="1" colspan="1">(0.24)</td><td align="left" valign="top" rowspan="1" colspan="1">0.68</td><td align="left" valign="top" rowspan="1" colspan="1">(0.23)</td><td align="left" valign="top" rowspan="1" colspan="1">0.64</td><td align="left" valign="top" rowspan="1" colspan="1">(0.23)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Composite SVI</td><td align="left" valign="top" rowspan="1" colspan="1">0.53</td><td align="left" valign="top" rowspan="1" colspan="1">(0.24)</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">(0.24)</td><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="left" valign="top" rowspan="1" colspan="1">(0.24)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Prior year social risk (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Justice involved</td><td align="left" valign="top" rowspan="1" colspan="1">2178</td><td align="left" valign="top" rowspan="1" colspan="1">(9.6)</td><td align="left" valign="top" rowspan="1" colspan="1">1127</td><td align="left" valign="top" rowspan="1" colspan="1">(8.9)</td><td align="left" valign="top" rowspan="1" colspan="1">835</td><td align="left" valign="top" rowspan="1" colspan="1">(21.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Unhoused</td><td align="left" valign="top" rowspan="1" colspan="1">7502</td><td align="left" valign="top" rowspan="1" colspan="1">(33.0)</td><td align="left" valign="top" rowspan="1" colspan="1">4783</td><td align="left" valign="top" rowspan="1" colspan="1">(37.8)</td><td align="left" valign="top" rowspan="1" colspan="1">2339</td><td align="left" valign="top" rowspan="1" colspan="1">(59.8)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Prior year health service use (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Emergency department visits</td><td align="left" valign="top" rowspan="1" colspan="1">2.25</td><td align="left" valign="top" rowspan="1" colspan="1">(3.81)</td><td align="left" valign="top" rowspan="1" colspan="1">2.54</td><td align="left" valign="top" rowspan="1" colspan="1">(4.23)</td><td align="left" valign="top" rowspan="1" colspan="1">3.81</td><td align="left" valign="top" rowspan="1" colspan="1">(5.67)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Psychiatric admissions</td><td align="left" valign="top" rowspan="1" colspan="1">0.59</td><td align="left" valign="top" rowspan="1" colspan="1">(1.09)</td><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="left" valign="top" rowspan="1" colspan="1">(1.20)</td><td align="left" valign="top" rowspan="1" colspan="1">1.80</td><td align="left" valign="top" rowspan="1" colspan="1">(2.05)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Non&#8208;psychiatric admissions</td><td align="left" valign="top" rowspan="1" colspan="1">0.97</td><td align="left" valign="top" rowspan="1" colspan="1">(1.59)</td><td align="left" valign="top" rowspan="1" colspan="1">0.96</td><td align="left" valign="top" rowspan="1" colspan="1">(1.74)</td><td align="left" valign="top" rowspan="1" colspan="1">2.65</td><td align="left" valign="top" rowspan="1" colspan="1">(2.84)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Prior year overdose history (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Opioid</td><td align="left" valign="top" rowspan="1" colspan="1">731</td><td align="left" valign="top" rowspan="1" colspan="1">(3.2)</td><td align="left" valign="top" rowspan="1" colspan="1">321</td><td align="left" valign="top" rowspan="1" colspan="1">(2.5)</td><td align="left" valign="top" rowspan="1" colspan="1">158</td><td align="left" valign="top" rowspan="1" colspan="1">(4.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other, non&#8208;opioid</td><td align="left" valign="top" rowspan="1" colspan="1">1242</td><td align="left" valign="top" rowspan="1" colspan="1">(5.5)</td><td align="left" valign="top" rowspan="1" colspan="1">570</td><td align="left" valign="top" rowspan="1" colspan="1">(4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">413</td><td align="left" valign="top" rowspan="1" colspan="1">(10.6)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Elixhauser index (mean, SD)</td><td align="left" valign="top" rowspan="1" colspan="1">3.86</td><td align="left" valign="top" rowspan="1" colspan="1">(2.29)</td><td align="left" valign="top" rowspan="1" colspan="1">4.11</td><td align="left" valign="top" rowspan="1" colspan="1">(2.39)</td><td align="left" valign="top" rowspan="1" colspan="1">5.08</td><td align="left" valign="top" rowspan="1" colspan="1">(2.51)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Prior year substance use history (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Alcohol use disorder</td><td align="left" valign="top" rowspan="1" colspan="1">8606</td><td align="left" valign="top" rowspan="1" colspan="1">(37.9)</td><td align="left" valign="top" rowspan="1" colspan="1">5253</td><td align="left" valign="top" rowspan="1" colspan="1">(41.5)</td><td align="left" valign="top" rowspan="1" colspan="1">3417</td><td align="left" valign="top" rowspan="1" colspan="1">(87.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Tobacco use disorder</td><td align="left" valign="top" rowspan="1" colspan="1">12&#8201;299</td><td align="left" valign="top" rowspan="1" colspan="1">(54.1)</td><td align="left" valign="top" rowspan="1" colspan="1">6810</td><td align="left" valign="top" rowspan="1" colspan="1">(53.8)</td><td align="left" valign="top" rowspan="1" colspan="1">2849</td><td align="left" valign="top" rowspan="1" colspan="1">(72.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other drug use disorder</td><td align="left" valign="top" rowspan="1" colspan="1">11&#8201;783</td><td align="left" valign="top" rowspan="1" colspan="1">(51.9)</td><td align="left" valign="top" rowspan="1" colspan="1">6651</td><td align="left" valign="top" rowspan="1" colspan="1">(52.6)</td><td align="left" valign="top" rowspan="1" colspan="1">3064</td><td align="left" valign="top" rowspan="1" colspan="1">(78.3)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Prior year mental health history (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Anxiety disorder</td><td align="left" valign="top" rowspan="1" colspan="1">13&#8201;011</td><td align="left" valign="top" rowspan="1" colspan="1">(57.3)</td><td align="left" valign="top" rowspan="1" colspan="1">5631</td><td align="left" valign="top" rowspan="1" colspan="1">(44.5)</td><td align="left" valign="top" rowspan="1" colspan="1">3055</td><td align="left" valign="top" rowspan="1" colspan="1">(78.1)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Bipolar disorder</td><td align="left" valign="top" rowspan="1" colspan="1">2988</td><td align="left" valign="top" rowspan="1" colspan="1">(13.2)</td><td align="left" valign="top" rowspan="1" colspan="1">1569</td><td align="left" valign="top" rowspan="1" colspan="1">(12.4)</td><td align="left" valign="top" rowspan="1" colspan="1">999</td><td align="left" valign="top" rowspan="1" colspan="1">(25.5)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Depression</td><td align="left" valign="top" rowspan="1" colspan="1">15&#8201;153</td><td align="left" valign="top" rowspan="1" colspan="1">(66.7)</td><td align="left" valign="top" rowspan="1" colspan="1">7799</td><td align="left" valign="top" rowspan="1" colspan="1">(61.6)</td><td align="left" valign="top" rowspan="1" colspan="1">3148</td><td align="left" valign="top" rowspan="1" colspan="1">(80.5)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">PTSD</td><td align="left" valign="top" rowspan="1" colspan="1">9752</td><td align="left" valign="top" rowspan="1" colspan="1">(42.9)</td><td align="left" valign="top" rowspan="1" colspan="1">4410</td><td align="left" valign="top" rowspan="1" colspan="1">(34.9)</td><td align="left" valign="top" rowspan="1" colspan="1">2350</td><td align="left" valign="top" rowspan="1" colspan="1">(60.1)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Psychotic disorder</td><td align="left" valign="top" rowspan="1" colspan="1">1541</td><td align="left" valign="top" rowspan="1" colspan="1">(6.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1178</td><td align="left" valign="top" rowspan="1" colspan="1">(9.3)</td><td align="left" valign="top" rowspan="1" colspan="1">630</td><td align="left" valign="top" rowspan="1" colspan="1">(16.1)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Prior year medical history (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Chronic pain</td><td align="left" valign="top" rowspan="1" colspan="1">18&#8201;227</td><td align="left" valign="top" rowspan="1" colspan="1">(80.2)</td><td align="left" valign="top" rowspan="1" colspan="1">9990</td><td align="left" valign="top" rowspan="1" colspan="1">(79.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3213</td><td align="left" valign="top" rowspan="1" colspan="1">(82.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hepatitis C</td><td align="left" valign="top" rowspan="1" colspan="1">3873</td><td align="left" valign="top" rowspan="1" colspan="1">(17.0)</td><td align="left" valign="top" rowspan="1" colspan="1">2992</td><td align="left" valign="top" rowspan="1" colspan="1">(23.6)</td><td align="left" valign="top" rowspan="1" colspan="1">746</td><td align="left" valign="top" rowspan="1" colspan="1">(19.1)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Prior year treatment history (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Received long&#8208;acting opioids</td><td align="left" valign="top" rowspan="1" colspan="1">3122</td><td align="left" valign="top" rowspan="1" colspan="1">(13.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1594</td><td align="left" valign="top" rowspan="1" colspan="1">(12.6)</td><td align="left" valign="top" rowspan="1" colspan="1">72</td><td align="left" valign="top" rowspan="1" colspan="1">(1.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Received short&#8208;acting opioids</td><td align="left" valign="top" rowspan="1" colspan="1">10&#8201;060</td><td align="left" valign="top" rowspan="1" colspan="1">(44.3)</td><td align="left" valign="top" rowspan="1" colspan="1">5519</td><td align="left" valign="top" rowspan="1" colspan="1">(43.6)</td><td align="left" valign="top" rowspan="1" colspan="1">939</td><td align="left" valign="top" rowspan="1" colspan="1">(24.0)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Prior year treatment history (mean, SD)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Average opioid dose (MME)<sup>k</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">19.95</td><td align="left" valign="top" rowspan="1" colspan="1">(40.43)</td><td align="left" valign="top" rowspan="1" colspan="1">20.50</td><td align="left" valign="top" rowspan="1" colspan="1">(69.46)</td><td align="left" valign="top" rowspan="1" colspan="1">6.31</td><td align="left" valign="top" rowspan="1" colspan="1">(15.67)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Psychotherapy visits</td><td align="left" valign="top" rowspan="1" colspan="1">5.77</td><td align="left" valign="top" rowspan="1" colspan="1">(11.80)</td><td align="left" valign="top" rowspan="1" colspan="1">7.19</td><td align="left" valign="top" rowspan="1" colspan="1">(15.09)</td><td align="left" valign="top" rowspan="1" colspan="1">19.39</td><td align="left" valign="top" rowspan="1" colspan="1">(21.69)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Prior month prescription history (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Antidepressant</td><td align="left" valign="top" rowspan="1" colspan="1">11&#8201;055</td><td align="left" valign="top" rowspan="1" colspan="1">(48.7)</td><td align="left" valign="top" rowspan="1" colspan="1">5672</td><td align="left" valign="top" rowspan="1" colspan="1">(44.8)</td><td align="left" valign="top" rowspan="1" colspan="1">2706</td><td align="left" valign="top" rowspan="1" colspan="1">(69.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Benzodiazepine</td><td align="left" valign="top" rowspan="1" colspan="1">3054</td><td align="left" valign="top" rowspan="1" colspan="1">(13.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1371</td><td align="left" valign="top" rowspan="1" colspan="1">(10.8)</td><td align="left" valign="top" rowspan="1" colspan="1">289</td><td align="left" valign="top" rowspan="1" colspan="1">(7.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Non&#8208;benzodiazepine hypnotics</td><td align="left" valign="top" rowspan="1" colspan="1">2130</td><td align="left" valign="top" rowspan="1" colspan="1">(9.4)</td><td align="left" valign="top" rowspan="1" colspan="1">964</td><td align="left" valign="top" rowspan="1" colspan="1">(7.6)</td><td align="left" valign="top" rowspan="1" colspan="1">373</td><td align="left" valign="top" rowspan="1" colspan="1">(9.5)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Skeletal muscle relaxants</td><td align="left" valign="top" rowspan="1" colspan="1">3455</td><td align="left" valign="top" rowspan="1" colspan="1">(15.2)</td><td align="left" valign="top" rowspan="1" colspan="1">1686</td><td align="left" valign="top" rowspan="1" colspan="1">(13.3)</td><td align="left" valign="top" rowspan="1" colspan="1">484</td><td align="left" valign="top" rowspan="1" colspan="1">(12.4)</td></tr><tr><td colspan="7" style="padding-left:10%" align="left" valign="top" rowspan="1">Provider and facility characteristics</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Provider credential (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">MD/DO</td><td align="left" valign="top" rowspan="1" colspan="1">21&#8201;003</td><td align="left" valign="top" rowspan="1" colspan="1">(88.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1204</td><td align="left" valign="top" rowspan="1" colspan="1">(9.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1856</td><td align="left" valign="top" rowspan="1" colspan="1">(47.5)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">PA/NP</td><td align="left" valign="top" rowspan="1" colspan="1">791</td><td align="left" valign="top" rowspan="1" colspan="1">(3.5)</td><td align="left" valign="top" rowspan="1" colspan="1">224</td><td align="left" valign="top" rowspan="1" colspan="1">(1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">712</td><td align="left" valign="top" rowspan="1" colspan="1">(18.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">PharmD</td><td align="left" valign="top" rowspan="1" colspan="1">164</td><td align="left" valign="top" rowspan="1" colspan="1">(0.7)</td><td align="left" valign="top" rowspan="1" colspan="1">135</td><td align="left" valign="top" rowspan="1" colspan="1">(1.1)</td><td align="left" valign="top" rowspan="1" colspan="1">188</td><td align="left" valign="top" rowspan="1" colspan="1">(4.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">OTP clinic</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">(0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">10&#8201;146</td><td align="left" valign="top" rowspan="1" colspan="1">(80.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">(0.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other/undetermined</td><td align="left" valign="top" rowspan="1" colspan="1">763</td><td align="left" valign="top" rowspan="1" colspan="1">(3.4)</td><td align="left" valign="top" rowspan="1" colspan="1">943</td><td align="left" valign="top" rowspan="1" colspan="1">(7.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1155</td><td align="left" valign="top" rowspan="1" colspan="1">(29.5)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Provider specialty (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Behavioral/mental health</td><td align="left" valign="top" rowspan="1" colspan="1">18&#8201;810</td><td align="left" valign="top" rowspan="1" colspan="1">(82.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1609</td><td align="left" valign="top" rowspan="1" colspan="1">(12.7)</td><td align="left" valign="top" rowspan="1" colspan="1">2434</td><td align="left" valign="top" rowspan="1" colspan="1">(62.2)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Primary care/internal medicine</td><td align="left" valign="top" rowspan="1" colspan="1">1474</td><td align="left" valign="top" rowspan="1" colspan="1">(6.5)</td><td align="left" valign="top" rowspan="1" colspan="1">61</td><td align="left" valign="top" rowspan="1" colspan="1">(0.5)</td><td align="left" valign="top" rowspan="1" colspan="1">120</td><td align="left" valign="top" rowspan="1" colspan="1">(3.1)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Emergency medicine/hospitalist</td><td align="left" valign="top" rowspan="1" colspan="1">226</td><td align="left" valign="top" rowspan="1" colspan="1">(1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">(0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="left" valign="top" rowspan="1" colspan="1">(0.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="left" valign="top" rowspan="1" colspan="1">2211</td><td align="left" valign="top" rowspan="1" colspan="1">(9.7)</td><td align="left" valign="top" rowspan="1" colspan="1">830</td><td align="left" valign="top" rowspan="1" colspan="1">(6.6)</td><td align="left" valign="top" rowspan="1" colspan="1">1340</td><td align="left" valign="top" rowspan="1" colspan="1">(34.3)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">OTP clinic</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">(0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">10&#8201;146</td><td align="left" valign="top" rowspan="1" colspan="1">(80.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">(0.0)</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Facility type (<italic toggle="yes">n</italic>, %)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">VA Medical Center (VAMC)</td><td align="left" valign="top" rowspan="1" colspan="1">19&#8201;993</td><td align="left" valign="top" rowspan="1" colspan="1">(88.0)</td><td align="left" valign="top" rowspan="1" colspan="1">12&#8201;546</td><td align="left" valign="top" rowspan="1" colspan="1">(99.2)</td><td align="left" valign="top" rowspan="1" colspan="1">3600</td><td align="left" valign="top" rowspan="1" colspan="1">(92.0)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Outpatient health facility<xref rid="add16659-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2030</td><td align="left" valign="top" rowspan="1" colspan="1">(8.9)</td><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="left" valign="top" rowspan="1" colspan="1">(0.1)</td><td align="left" valign="top" rowspan="1" colspan="1">104</td><td align="left" valign="top" rowspan="1" colspan="1">(2.7)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other outpatient services</td><td align="left" valign="top" rowspan="1" colspan="1">260</td><td align="left" valign="top" rowspan="1" colspan="1">(1.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">(0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">(0.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="left" valign="top" rowspan="1" colspan="1">438</td><td align="left" valign="top" rowspan="1" colspan="1">(1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">89</td><td align="left" valign="top" rowspan="1" colspan="1">(0.7)</td><td align="left" valign="top" rowspan="1" colspan="1">192</td><td align="left" valign="top" rowspan="1" colspan="1">(4.9)</td></tr></tbody></table><table-wrap-foot id="add16659-ntgp-0001"><fn id="add16659-note-0001"><p>Abbreviations: BUP, buprenorphine; MET, methadone; MD/DO, medical doctor or doctor of osteopathy; MME, morphine milligram equivalents; MOUD, medication treatment for opioid use Disorder; OTP, opioid treatment program; PA/NP, physician assistant or nurse practitioner; PharmD, doctor of pharmacy; PTSD, post&#8208;traumatic stress disorder; SD, standard deviation; SVI, Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry Social Vulnerability Index; XR&#8208;NTX, extended&#8208;release naltrexone.</p></fn><fn id="add16659-note-0002"><label>
<sup>a</sup>
</label><p>Outpatient health facilities include Veteran Health Administration health care centers (HCCs) and community&#8208;based outpatient clinics (CBOCs).</p></fn></table-wrap-foot></table-wrap></sec><sec id="add16659-sec-0010"><title>Early discontinuation</title><p>Using the operational definition employed in other CTN research [<xref rid="add16659-bib-0042" ref-type="bibr">42</xref>], we determined that a discontinuation occurred when there was a gap in treatment exceeding 28&#8201;days. Because we are relying on EHR data, &#8216;gap&#8217; refers to the time between the last covered day from a previously documented fill (BUP) or administration (MET and XR&#8208;NTX) and the next documented receipt of the same medication. Early discontinuation was defined as discontinuing the initiated type of MOUD before completing 180&#8201;days of therapy. Medication data were taken from inpatient and outpatient dispensations.</p></sec><sec id="add16659-sec-0011"><title>Outcomes</title><p>Our primary outcome of interest was the probability of experiencing a fatal or non&#8208;fatal overdose in the 365&#8201;days following initiation. Of note, overdoses were not restricted to occurring only after early discontinuation. Fatal overdoses were identified using the VHA/DoD Mortality Data Repository [<xref rid="add16659-bib-0033" ref-type="bibr">33</xref>] and non&#8208;fatal overdoses were identified using VHA inpatient and outpatient visits and VHA&#8208;paid health&#8208;care encounters at non&#8208;VHA facilities [<xref rid="add16659-bib-0043" ref-type="bibr">43</xref>].</p><p>We also use the exposure to examine a secondary outcome, i.e. probability of early discontinuation, in an exploratory analysis of associated patient characteristics. These outcomes were predefined in our CTN&#8208;0142 protocol [<xref rid="add16659-bib-0031" ref-type="bibr">31</xref>, <xref rid="add16659-bib-0032" ref-type="bibr">32</xref>].</p></sec><sec id="add16659-sec-0012"><title>Other covariates</title><p>To adjust for possible confounding associated with health system and changes in the practice of care, we included derived measures of facility type where the initiation took place, credentials and specialty of the provider, and initiation fiscal year using the CDW data. Additional covariates for patient characteristics were selected based on existing literature establishing their association with overdose or MOUD retention [<xref rid="add16659-bib-0044" ref-type="bibr">44</xref>, <xref rid="add16659-bib-0045" ref-type="bibr">45</xref>, <xref rid="add16659-bib-0046" ref-type="bibr">46</xref>, <xref rid="add16659-bib-0047" ref-type="bibr">47</xref>, <xref rid="add16659-bib-0048" ref-type="bibr">48</xref>, <xref rid="add16659-bib-0049" ref-type="bibr">49</xref>, <xref rid="add16659-bib-0050" ref-type="bibr">50</xref>, <xref rid="add16659-bib-0051" ref-type="bibr">51</xref>, <xref rid="add16659-bib-0052" ref-type="bibr">52</xref>].</p><sec id="add16659-sec-0013"><title>Socio&#8208;demographic characteristics</title><p>We extracted basic demographic information: age at initiation, sex, self&#8208;reported race and ethnicity, employment status and marital status. To capture veteran&#8208;level social risk factors, we constructed measures of a history of justice involvement and being unhoused following methods used by previous researchers [<xref rid="add16659-bib-0053" ref-type="bibr">53</xref>]. We also included a categorical variable for the veteran's assigned VHA priority group from the most recent eligibility data prior to the index date. VHA priority status is a multi&#8208;faceted measure of health and social need, determined by factors such as military service history, disability rating, income level and Medicaid eligibility [<xref rid="add16659-bib-0054" ref-type="bibr">54</xref>]. For example, priority groups 1 and 4 have high levels of disability (the former due to service&#8208;connected injuries and the latter otherwise having catastrophic injuries preventing work). Priority status also helps to determine the co&#8208;payments that veterans pay.</p></sec><sec id="add16659-sec-0014"><title>Area characteristics</title><p>US Census regions were used to broadly capture geographic variations in care. We used RUCA Categorization B [<xref rid="add16659-bib-0055" ref-type="bibr">55</xref>] to assess rurality of residence. Categorization B provides a three&#8208;level measure of rurality: urban, large rural city/town and isolated small rural town. We used SVI measures to capture additional risk veterans may experience from their communities. The SVI has four themed measures of area risk: (1) &#8216;socio&#8208;economic status&#8217;, (2) &#8216;household characteristics&#8217;, (3) &#8216;racial and ethnic minority status&#8217; and (4) &#8216;housing type and transportation&#8217;.</p></sec><sec id="add16659-sec-0015"><title>Diagnosis and treatment characteristics</title><p>Using encounters in the 365&#8201;days before initiation, we assessed the presence of key comorbid diagnoses: tobacco use disorder, alcohol use disorder (AUD), other drug use disorder (e.g. cocaine use disorder, cannabis use disorder), major depression, psychotic disorder, post&#8208;traumatic stress disorder, anxiety disorders, bipolar disorder, hepatitis C and chronic pain. Using the same encounters, we determined if the veteran had a history of opioid overdose, and constructed a count of Elixhauser comorbidities [<xref rid="add16659-bib-0056" ref-type="bibr">56</xref>] and several measures of health service use (emergency room visits, psychotherapy visits, inpatient admissions, psychiatric admission). We included additional medication&#8208;specific, proximal factors (receipt of prescription opioids, sedatives, benzodiazepines or antidepressants) to help capture the patient's clinical complexity. For medication&#8208;specific factors, we captured medication receipt only in the 30&#8201;days before initiation under the assumption that recent exposure better indicates active treatment of the veteran's comorbidities.</p></sec></sec><sec id="add16659-sec-0016"><title>Statistical analyses</title><p>All analyses were stratified by cohort; that is, we estimated a separate model for each MOUD type and results cannot be statistically compared across models. The initial specification for each model used all hypothesized covariates in the equations for early discontinuation and overdose but also included discontinuation as a predictor in the overdose equation. Models were refined using a process described in the Supporting <xref rid="add16659-supitem-0001" ref-type="supplementary-material">information</xref>, but always included age, sex and ethnicity. We pre&#8208;specified a 95% confidence level for tests and confidence intervals (CIs). We used SAS version 8.3 and SQL for data manipulation and Stata version 17.0 for analyses.</p><sec id="add16659-sec-0017"><title>Statistical model</title><p>We hypothesized that there are unobserved (in the data) patient&#8208;specific factors that determine the probability of overdose, and that these factors are correlated with similarly unobserved patient&#8208;specific factors that are associated with the probability of early discontinuation, a phenomenon referred to in some disciplines as &#8216;endogeneity&#8217;. To account for this possible endogeneity, we used a bivariate probit model [<xref rid="add16659-bib-0049" ref-type="bibr">49</xref>, <xref rid="add16659-bib-0057" ref-type="bibr">57</xref>, <xref rid="add16659-bib-0058" ref-type="bibr">58</xref>]. A bivariate probit model extends a conventional probit model to permit two outcomes of interest to be analyzed simultaneously, including the case where one &#8216;outcome&#8217; is a covariate in the other equation. Our model estimates both the relationship between probability of overdose and early discontinuation, controlling for observed covariates, and simultaneously the relationship between probability of early discontinuation and the observed covariates. Together with the usual coefficient estimates of a probit model, this approach estimates &#120588;, the correlation between the error terms in the overdose and discontinuation equations.</p></sec><sec id="add16659-sec-0018"><title>Predicted probabilities and incremental effects</title><p>A probit model, like a logistic model, is used for binary outcomes to ensure that predictions of the outcome are strictly between 0 and 1. Unlike a logistic model, the coefficients from a probit model cannot be transformed into commonly presented measures; for example, odds ratios. We adopt two approaches to interpreting the results. First, for our main analysis, we report the average predicted probability for a counterfactual: given the within&#8208;sample observed characteristics of each MOUD cohort, what probability of overdose would we expect if there had been no early discontinuations in the sample. This type of counterfactual analysis is useful for highlighting what is realistically possible to achieve taking all other existing characteristics of patients as fixed, and is different from simply computing the probability of overdose among those who do not actually discontinue within the sample.</p><p>Alternately, these models are often interpreted using the average marginal effect of each covariate or, in the case of a binary or categorical covariate, the average incremental effect (IE). In binary models, the IE measures changes directly on the probability scale. Average IEs are the sample&#8208;average change in the outcome given a change in a predictor while holding all other covariates as observed, similar to interpretation of coefficients for linear regression. They are obtained by taking the average of the difference in predicted probabilities when all subjects in the sample have the exposure of interest (early discontinuation) compared to when no subjects have the exposure, regardless of the actual experience of early discontinuation. For the primary outcome, we computed the average IE of early discontinuation on the probability of overdose.</p><p>An alternative approach to computing IEs is to evaluate them where covariates are held to specified values, rather than averaging effects over the sample. This approach, computing the IE at a representative value, is valuable because the effect of each deviation from the representative value can be examined in isolation instead of a sample&#8208;dependent average. We adopt this approach for our exploratory analysis of patient covariates associated with probability of early discontinuation. A detailed description of selecting the &#8216;representative&#8217; patient is shown in the Supporting <xref rid="add16659-supitem-0001" ref-type="supplementary-material">information</xref>.</p></sec></sec></sec><sec sec-type="results" id="add16659-sec-0019"><title>RESULTS</title><sec id="add16659-sec-0020"><title>Early discontinuation and probability of overdose</title><p>Table&#160;<xref rid="add16659-tbl-0002" ref-type="table">2</xref> presents the results from our primary analysis. The first row of panel I shows the sample average predicted probability of overdose if no veterans in the cohort discontinued early but otherwise kept all their same characteristics. Among veterans who initiated BUP, the predicted probability is 3.9% (95% CI&#8201;=&#8201;3.2 to 4.6%). This can be compared to the observed rate of 9.0% from Table&#160;<xref rid="add16659-tbl-0001" ref-type="table">1</xref>. Results for MET and XR&#8208;NTX are interpreted analogously, with predicted probabilities of 8.4% (MET) and 4.5% (XR&#8208;NTX), although the XR&#8208;NTX estimate cannot be statistically differentiated from 0. The observed rates of overdose from Table&#160;<xref rid="add16659-tbl-0001" ref-type="table">1</xref> is 8.0% among MET initiators and 12.2% among XR&#8208;NTX initiators.</p><table-wrap position="float" id="add16659-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Effect of early discontinuation on overdose by MOUD type.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">BUP</th><th align="left" valign="bottom" rowspan="1" colspan="1">MET</th><th align="left" valign="bottom" rowspan="1" colspan="1">XR&#8208;NTX</th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" rowspan="1">Panel I</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Predicted Pr of overdose without early discontinuation</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>3.9%</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>8.4%</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">4.5%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">[3.2%, 4.6%]</td><td align="left" valign="top" rowspan="1" colspan="1">[3.3%, 13.4%]</td><td align="left" valign="top" rowspan="1" colspan="1">[&#8722;6.7%, 15.7%]</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IE of early discontinuation</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>14.0</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#8722;0.5</td><td align="left" valign="top" rowspan="1" colspan="1">9.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">[9.4, 18.6]</td><td align="left" valign="top" rowspan="1" colspan="1">[&#8722;6.2, 5.2]</td><td align="left" valign="top" rowspan="1" colspan="1">[&#8722;7.9, 27.0]</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Panel II</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#961;</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>&#8722;0.350</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">0.072</td><td align="left" valign="top" rowspan="1" colspan="1">&#8722;0.217</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">[&#8722;0.493, &#8722;0.189]</td><td align="left" valign="top" rowspan="1" colspan="1">[&#8722;0.153, 0.291]</td><td align="left" valign="top" rowspan="1" colspan="1">[&#8722;0.845, 0.663]</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#967;<sup>2(1)</sup>: &#961;&#8201;=&#8201;0</td><td align="left" valign="top" rowspan="1" colspan="1">16.9121</td><td align="left" valign="top" rowspan="1" colspan="1">0.3880</td><td align="left" valign="top" rowspan="1" colspan="1">0.1798</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>&#8208;value</td><td align="left" valign="top" rowspan="1" colspan="1">0.0000</td><td align="left" valign="top" rowspan="1" colspan="1">0.5334</td><td align="left" valign="top" rowspan="1" colspan="1">0.6716</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">BIC</td><td align="left" valign="top" rowspan="1" colspan="1">42956.74</td><td align="left" valign="top" rowspan="1" colspan="1">17200.32</td><td align="left" valign="top" rowspan="1" colspan="1">6510.56</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Number of observations</td><td align="left" valign="top" rowspan="1" colspan="1">22&#8201;721</td><td align="left" valign="top" rowspan="1" colspan="1">12&#8201;652</td><td align="left" valign="top" rowspan="1" colspan="1">3911</td></tr></tbody></table><table-wrap-foot id="add16659-ntgp-0002"><fn id="add16659-note-0004"><p>
<italic toggle="yes">Note</italic>: Items in bold type are significantly different from zero at the 5% or lower level.</p></fn><fn id="add16659-note-0003"><p>Abbreviations: BUP, buprenorphine; IE, incremental effect; MET, methadone; MOUD, medication treatment for opioid use disorder; Pr, probability; XR&#8208;NTX, extended&#8208;release naltrexone.</p></fn></table-wrap-foot></table-wrap><p>A statistically significant average IE of early discontinuation was found only in the BUP cohort, with an average increased probability of 14.0 percentage points (95% CI&#8201;=&#8201;9.4 to 18.6) after early discontinuation, all else being constant. The IE for XR&#8208;NTX was consistent in size and direction with early discontinuation increasing the probability of overdose, but there is insufficient precision to distinguish it from zero [9.5 percentage points (95% CI&#8201;=&#8201;&#8722;7.9 to 27.0)]. The estimated IE of early discontinuation among MET initiators was &#8722;0.5 percentage points (95% CI&#8201;=&#8201;&#8722;6.2 to 5.2), which is not statistically significant.</p><p>Panel II shows the correlation between the two error terms. Among BUP initiators, <italic toggle="yes">&#961;</italic> is &#8722;0.350 and significantly different from 0. This is consistent with our hypothesis, that unmeasured factors associated with early discontinuation are correlated with unmeasured factors that predict overdose. The estimate of <italic toggle="yes">&#961;</italic> for XR&#8208;NTX is of similar magnitude and direction but cannot be statistically distinguished from 0. The estimate for MET is smaller, positive and not statistically significant. Full final model specifications are available from the corresponding author upon request.</p></sec><sec id="add16659-sec-0021"><title>Patient characteristics and probability of early discontinuation</title><p>The predicted probability of early discontinuation for the representative patient was 45.2% in the BUP cohort (Figure&#160;<xref rid="add16659-fig-0001" ref-type="fig">1</xref>), 79.7% in the MET cohort (Figure&#160;<xref rid="add16659-fig-0002" ref-type="fig">2</xref>), and 78.7% in the XR&#8208;NTX cohort (Figure&#160;<xref rid="add16659-fig-0003" ref-type="fig">3</xref>). Figures&#160;<xref rid="add16659-fig-0001" ref-type="fig">1</xref>, <xref rid="add16659-fig-0002" ref-type="fig">2</xref>, <xref rid="add16659-fig-0003" ref-type="fig">3</xref> also display the IEs and 95% CIs for deviations from the representative patient's characteristics, computed using each cohort's final model (underlying numeric values in Supporting information, Tables&#160;<xref rid="add16659-supitem-0002" ref-type="supplementary-material">S2</xref>&#8211;<xref rid="add16659-supitem-0002" ref-type="supplementary-material">S4</xref>). Characteristics with CIs that do not cross the 0.0 line are statistically different from 0 at the 95% level, and are shown in dark blue. The IEs of dropped covariates are, by definition, 0. These, together with any non&#8208;patient characteristics that are in the model, are excluded from the calculation of the patient characteristic IEs. Because patient characteristics were included in this exploratory analysis only if they had a statistically significant association in the cohort&#8208;specific model, the number of characteristics varied by MOUD type, ranging from 14 (XR&#8208;NTX) to 25 (BUP).</p><fig position="float" fig-type="FIGURE" id="add16659-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Difference from representative patient for selected patient characteristics in predicted probability of early discontinuation of buprenorphine (BUP) with 95% confidence intervals.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ADD-120-138-g002.jpg"/></fig><fig position="float" fig-type="FIGURE" id="add16659-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Difference from representative patient for selected patient characteristics in predicted probability of early discontinuation of met with 95% confidence intervals.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ADD-120-138-g003.jpg"/></fig><fig position="float" fig-type="FIGURE" id="add16659-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Difference in predicted probability of early discontinuation of extended&#8208;release naltrexone (XR&#8208;NTX) based on patient characteristics.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ADD-120-138-g001.jpg"/></fig><p>Each IE is the change when the listed characteristic takes the value shown instead of the value for the reference patient, with all other patient characteristics fixed at those of the reference patient. Taking the first statistically significant IE shown, if a veteran in the BUP cohort was aged 20&#8201;years instead of the 50&#8201;years specified for our reference patient yet otherwise has exactly the same characteristics as the reference patient, the predicted probability of early discontinuation is 10.7 percentage points higher (95% CI&#8201;=&#8201;8.5 to 12.9). Additional examples of interpretation of these figures can be found in the Supporting <xref rid="add16659-supitem-0001" ref-type="supplementary-material">information</xref>.</p></sec></sec><sec sec-type="discussion" id="add16659-sec-0022"><title>DISCUSSION</title><p>In a large, national sample of veterans initiating one of three types of MOUD, we evaluated the association between early discontinuation and overdose for each of three medications. We found that, given the characteristics of patients initiated on BUP within the VA, early discontinuation is associated with a statistically significant increased predicted probability of fatal or non&#8208;fatal overdose for BUP. The direction of association was the same and the estimated magnitude was similar for XR&#8208;NTX, but the association was not statistically significant, probably due to the much smaller sample size. By contrast, the estimated incremental effect of early discontinuation on overdose probability in the cohort that was initiated on MET was both close to zero and not statistically significant. When we examined patient characteristics linked to early discontinuation in our exploratory analysis, we found little commonality in specific predictors among medications.</p><p>Our findings regarding overdose probability in the BUP cohort are consistent with studies showing worse patient outcomes among those discontinuing BUP early [<xref rid="add16659-bib-0013" ref-type="bibr">13</xref>, <xref rid="add16659-bib-0059" ref-type="bibr">59</xref>, <xref rid="add16659-bib-0060" ref-type="bibr">60</xref>] and reiterate the importance of retention among BUP initiators. Specifically, given the overdose risk profile associated with the observed characteristics of the veterans, their providers and the type of facility where they initiated, we would have expected to see a substantially lower rate of overdose (approximately 3.9%) than we actually observed (approximately 9.0%) at the current rate of early discontinuation. Interventions that aim to improve retention, such as the Stepped Care for Opioid Use Train&#8208;the&#8208;Trainer (SCOUTT) program [<xref rid="add16659-bib-0061" ref-type="bibr">61</xref>], thus appear likely to result in long&#8208;term improvements in the more distal outcome of overdose. Our results for the XR&#8208;NTX cohort are also consistent with previous findings [<xref rid="add16659-bib-0062" ref-type="bibr">62</xref>, <xref rid="add16659-bib-0063" ref-type="bibr">63</xref>]. Although high variation among the relatively small number of XR&#8208;NTX initiators meant that we did not achieve sufficient precision to statistically distinguish these numbers; the alignment with BUP and prior results suggests that the same analysis in a larger sample of XR&#8208;NTX initiators would be statistically significant.</p><p>By contrast, we found that MET initiators had the highest predicted probability of overdose if all early discontinuations were prevented (8.4%), a rate that tracked closely to the observed rate (8.0%) in our sample. We also found higher rates of MET discontinuation. This may seem to counter previous literature. For example, a 2017 meta&#8208;analysis of cohort studies found retention on MET (and BUP) is associated with substantial reductions in risk for all cause and overdose mortality [<xref rid="add16659-bib-0060" ref-type="bibr">60</xref>]. Our study is not directly comparable to such work, but rather because the use of average predicted probabilities within a cohort focuses upon the effect of an exposure in that population. The veteran population, and especially the population that is initiated on MET within VHA, differs substantially from the patient population in a typical cohort study. For example, those initiating MET, compared to those initiating BUP or XR&#8208;NTX, were more likely to have hepatitis C, indicative of possible intravenous (IV) drug use and probably more severe OUD. Our work is better compared to other studies among veterans; for example, a recent study found higher retention rates among veterans receiving BUP compared to those receiving MET, also seemingly in contradiction to past research [<xref rid="add16659-bib-0030" ref-type="bibr">30</xref>]. Our counterintuitive findings may reflect a shift in which patients are receiving different types of MOUD within VHA. As BUP has become more prevalent in more recent years VHA clinicians may be initiating patients at a higher baseline risk of overdose on MET, as treatment with MET comes with daily dosing and the structure of the opioid treatment program. In addition, subtherapeutic dosing of MET within VHA could be contributing to these findings. While VHA data do not allow for quantification of MET dosing, we have conferred with directors of OTPs in VHA who have noted that dosing is usually quite low. If that is true, subtherapeutic MET dosing could lead to continued illicit opioid use, which would contribute to both lower rates of retention and no difference in overdose risk. Our finding that MET initiators had the highest baseline risk in the absence of early discontinuation supports this supposition.</p><p>We found that patient characteristics with statistically significant changes in the predicted probability varied greatly by MOUD type. We focus our discussion on specific differences that we believe are of policy or clinical importance. We also focus here on BUP and XR&#8208;NTX because of the lack of relationship between early discontinuation and overdose for MET in the cohort initiated on MET. Consistent with past research finding that geographic region is significantly associated with MOUD retention [<xref rid="add16659-bib-0064" ref-type="bibr">64</xref>], we found that at least some geographies were associated with significantly different probabilities of retention, with the direction and magnitude of the effect varying by type of MOUD and region of the country where the veteran lives. More research is warranted into how patterns of clinical care may systematically differ within VHA across these regions or if the differences may instead be driven by societal factors, perhaps even beyond the health&#8208;care system, that vary based on where individuals live (e.g. availability of public transportation, social support for addiction therapy, levels of stigma). The fact that each of the four domains of the SVI (i.e. socio&#8208;economic status, household characteristics, racial and ethnic minority status and housing type and transportation) were highly significant suggests that changes at the societal or health system level (i.e. structural changes), rather than specific factors under the clinician's control, may be necessary. However, for BUP and XR&#8208;NTX, we found a clear pattern where an increase in the number of prior year psychotherapy visits corresponded to a decrease in predicted probability of early discontinuation for the representative patient, potentially indicating the clinician's use of psychotherapy before or together with MOUD may be beneficial, providing a modifiable intervention at the clinician level.</p><p>For BUP, being employed and in the economically affluent priority groups 8A&#8211;8G was associated with a decreased predicted probability of early discontinuation compared to the reference patient, which is consistent with past research showing that employment is associated with greater BUP retention [<xref rid="add16659-bib-0065" ref-type="bibr">65</xref>]. While income and employment are not modifiable through any health system intervention, it is surprising that we found effects even within VHA, where the financial barriers to obtaining care are extremely low. This suggests that the employment and income covariates may be detecting the effect of an unmeasured confounder that is associated with the likelihood of being employed and higher income. Being married was also protective for BUP initiators. Employment and being married may be proxy measures for social support, which indicates that various forms of wrap&#8208;around social services may be beneficial. It is also worth highlighting the role of comorbid AUD within the XR&#8208;NTX cohort, where we observed an AUD diagnosis associated with a higher predicted probability of early discontinuation compared to the reference patient. This is consistent with past research finding that patients with co&#8208;occurring OUD and AUD have higher retention rates when prescribed BUP or MET [<xref rid="add16659-bib-0066" ref-type="bibr">66</xref>]. XR&#8208;NTX is Food and Drug Administration (FDA) approved for the treatment of AUD, and AUD was more prevalent among veterans who initiated XR&#8208;NTX compared to the BUP or MET cohorts. Given that AUD was associated with a higher probability of early XR&#8208;NTX discontinuation, but not with early BUP discontinuation, future research needs to explore whether BUP may be a better choice for veterans with comorbid OUD and AUD [<xref rid="add16659-bib-0015" ref-type="bibr">15</xref>].</p><p>Finally, self&#8208;identifying as Black was associated with greater predicted probability of early discontinuation among BUP initiators [<xref rid="add16659-bib-0043" ref-type="bibr">43</xref>]. We observed a similar relationship when veterans initiated on BUP reside in a high&#8208;vulnerability area for the &#8216;racial and ethnic minority status&#8217; SVI theme. Past research has found that patients who are Black, compared to those who are White, are significantly less likely to receive an adequate dose of BUP (defined as at least 8&#160;mg/day) [<xref rid="add16659-bib-0067" ref-type="bibr">67</xref>], and that higher BUP doses are associated with better retention [<xref rid="add16659-bib-0015" ref-type="bibr">15</xref>, <xref rid="add16659-bib-0068" ref-type="bibr">68</xref>]. Interestingly, a systematic review of MOUD retention found that, for BUP, retention of patients who are Black was significantly higher in clinical trials compared to retrospective chart review studies [<xref rid="add16659-bib-0069" ref-type="bibr">69</xref>]. This finding is consistent with worse quality BUP care for patients who are Black in clinical practice [<xref rid="add16659-bib-0067" ref-type="bibr">67</xref>], a bias less likely to manifest in clinical trials that use a standard dosing procedure for all participants and have research teams that are motivated to engage and retain patients. Caution is required in interpreting these findings, however, because we did not have access to dosing data, mainly for MET, and other potentially important predictors of outcomes by MOUD. Nevertheless, given the dramatic increase in overdoses in people who are Black [<xref rid="add16659-bib-0070" ref-type="bibr">70</xref>, <xref rid="add16659-bib-0071" ref-type="bibr">71</xref>] and our finding that BUP retention is protective against overdose, this is a clinically important finding that warrants further evaluation.</p><p>While early [<xref rid="add16659-bib-0065" ref-type="bibr">65</xref>, <xref rid="add16659-bib-0066" ref-type="bibr">66</xref>, <xref rid="add16659-bib-0072" ref-type="bibr">72</xref>, <xref rid="add16659-bib-0073" ref-type="bibr">73</xref>] MET discontinuation was not a significant factor in predicting overdose, several of our findings merit mention. First, the observed rate of early discontinuation of MET is much higher in the current study compared to previously reported rates [<xref rid="add16659-bib-0008" ref-type="bibr">8</xref>, <xref rid="add16659-bib-0009" ref-type="bibr">9</xref>, <xref rid="add16659-bib-0015" ref-type="bibr">15</xref>, <xref rid="add16659-bib-0074" ref-type="bibr">74</xref>]. In addition to being indicative of a higher baseline risk for detrimental outcomes, this may reflect a tendency to use lower MET doses in the VA (personal communication with OTP clinicians). If MET doses are suboptimal, this could account for the better retention of individuals without a history of opioid overdose who may be clinically less complex or have less severe addictions. Our finding that having more than one racial identity was associated with a significantly increased predicted probability of early discontinuation for MET is an association that has not been previously reported, which may simply reflect the under&#8208;representation of this racial identity in MOUD research [<xref rid="add16659-bib-0072" ref-type="bibr">72</xref>].</p><sec id="add16659-sec-0023"><title>Limitations</title><p>Like all studies that rely upon administrative data, our study is subject to potential measurement and classification error in key variables. We cannot accurately discern when MOUD discontinuation occurred by relying on prescription records: a greater concern with BUP, as it relies more heavily on the prescription runout date. In addition, a small number of BUP initiations made through the opioid treatment program may have been misclassified, as we assumed that all dispensations made through the opioid treatment program were MET dispensations because the data do not support distinguishing between the two [<xref rid="add16659-bib-0030" ref-type="bibr">30</xref>]. Similarly, the use of clinic stop codes provides minimal information on receipt of MET (e.g. does not contain MET dose), and therefore probably introduces some degree of measurement error that is difficult to quantify. VHA CDW data is also limited to records for veterans who received care from a VHA facility or whose community&#8208;based care was paid for by VHA. To the extent that VHA users substituted for non&#8208;VHA care instead of discontinuing therapy, we would overcount early discontinuations. Additionally, we did not account for switching between different forms of MOUD. We focused upon discontinuation of the initiated MOUD, given its status as a probable indicator of failure of the first treatment&#8208;attempted MOUD type. However, treating switches as discontinuations may obscure the relationship between discontinuation and overdose. Excluding individuals who switched from the analysis might have resulted in larger point estimates for the IE of early discontinuation, but would have been obtained at the cost of a smaller sample size.</p><p>Overdose deaths are undercounted to the extent that drug involvement is under&#8208;reported on death certificates; some estimates put true rates as much as 20&#8211;35% higher than reported [<xref rid="add16659-bib-0075" ref-type="bibr">75</xref>]. Similarly, non&#8208;fatal overdoses that do not result in a health&#8208;care visit or for which VHA does not pay for care are not captured in our data. A recent study found that the sensitivity of diagnostic codes for overdose, compared to self&#8208;report, varied by 12.0% for opioids with diagnosis codes undercounting overdoses, which could underestimate the association between early MOUD discontinuation and overdose risk [<xref rid="add16659-bib-0076" ref-type="bibr">76</xref>]. However, this is only a concern if the rate of undercounting differs by MOUD type. We are not able to capture illicit fentanyl or heroin consumption or route of drug administration with these administrative data, which have been shown to be significant predictors of relapse and overdose [<xref rid="add16659-bib-0077" ref-type="bibr">77</xref>]. In addition, the role of fentanyl and its analogs in the rise of overdose rates emerged during this time&#8208;frame, with rapid growth occurring from 2015 to 2021, encompassing the second portion of this time&#8208;frame. Given these temporal changes, there may be substantial heterogeneity in overdose risk and predictors of discontinuation between these time&#8208;periods [<xref rid="add16659-bib-0078" ref-type="bibr">78</xref>]. Our results also may not generalize to other populations; the US veteran population differs substantially from the broader US population in terms of demographics (e.g. disproportionately male) and exposure and health history.</p><p>Caution is needed when comparing our results to existing studies that have examined the efficacy of different MOUD types. While our models adjust for a wide array of observable risks, many factors are unmeasured and unmeasurable in administrative data. For example, many individual&#8208;level social determinants of health (e.g. social support structures, familial relationships) may be observable to the clinician and influence treatment selection but generally cannot be measured in studies such as this, which rely upon administrative data. Relatedly, dose, particularly BUP dose, has been previously linked to early MOUD discontinuation and was not included as a covariate here due to identification of MOUD type by stop codes and CPT codes&#160;[<xref rid="add16659-bib-0068" ref-type="bibr">68</xref>]. Therefore, studies that assess multiple treatment options (e.g. comparing OUD treatment pathways, comparing MOUD types) but do not appropriately account for non&#8208;random treatment assignment are probably subject to selection bias. By contrast, all analyses conducted in this study take MOUD treatment type as given, so interpretation of our results is conditional upon treatment assignment. While this approach limits the ability to make statements about which type of MOUD should be preferred for which patient, it is appropriate for our goal of highlighting differences in patient&#8208;related risk factors across MOUD types and is not subject to selection bias.</p></sec></sec><sec sec-type="conclusions" id="add16659-sec-0024"><title>CONCLUSIONS</title><p>Early discontinuation of BUP, and probably XR&#8208;NTX, is associated with a greater probability of experiencing a fatal or non&#8208;fatal overdose; we did not find the same association with MET. The lack of a consistent set of characteristics means that clinicians need to customize their focus on different characteristics to increase the probability of retention depending on the MOUD type initiated. Many influential predictive characteristics found in this study are modifiable only at the societal or health system level and thus lend themselves more to structural interventions, such as de&#8208;stigmatizing OUD treatment or better public transportation. While few specific factors are under the clinician's control, these findings indicate that personalizing the prescribing decision to avoid medications when the patient has an attribute associated with a greater probability of early discontinuation of that medication may ultimately improve retention on MOUD therapy, and thus outcomes on key metrics such as overdose.</p></sec><sec id="add16659-sec-0029"><title>AUTHOR CONTRIBUTIONS</title><p>
<bold>Corey J. Hayes:</bold> Conceptualization; data curation; funding acquisition; methodology; project administration; writing&#8212;original draft. <bold>Rebecca A. Raciborski:</bold> Conceptualization; statistical analysis; methodology; writing&#8212;review and editing. <bold>Matthew Nowak:</bold> Methodology; writing&#8212;original draft. <bold>Mahip Acharya:</bold> Conceptualization; methodology; writing&#8212;review and editing. <bold>Edward V. Nunes:</bold> Conceptualization; methodology; writing&#8212;review and editing. <bold>T. John Winhusen:</bold> Conceptualization; funding acquisition; methodology; project administration; supervision; writing&#8212;review and editing.</p></sec><sec id="add16659-sec-0025"><title>DECLARATIONS OF INTEREST</title><p>None to declare.</p></sec><sec id="add16659-sec-0026"><title>DISCLAIMER</title><p>The content of this work does not represent the views of the US Department of Veterans Affairs, the National Institutes of Health or the United States Government.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="add16659-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Data S1.</bold> Supporting information.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ADD-120-138-s002.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="add16659-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S1.</bold> Derivation of the Study Cohort.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ADD-120-138-s001.png" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="add16659-sec-1025"><title>ACKNOWLEDGEMENTS</title><p>This work was supported by the National Institute on Drug Abuse of the National Institutes of Health [UG1DA013732&#8208;23S3] under the CTN&#8208;0142 protocol. C.J.H. was also supported by a VA Health Services Research an Development Career Development Award&#8208;2 (IK2HX003358).</p></ack><sec sec-type="data-availability" id="add16659-sec-0028"><title>DATA AVAILABILITY STATEMENT</title><p>Research data are not shared.</p></sec><ref-list id="add16659-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="add16659-bib-0001"><label>1</label><mixed-citation publication-type="book" id="add16659-cit-0002"><string-name name-style="western"><surname>Mancher</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Leshner</surname><given-names>AI</given-names></string-name>. <source>Medications for Opioid Use Disorder Save Lives</source><publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Academies Press</publisher-name>; <year>2019</year>.<pub-id pub-id-type="pmid">30896911</pub-id></mixed-citation></ref><ref id="add16659-bib-0002"><label>2</label><mixed-citation publication-type="miscellaneous" id="add16659-cit-0003"><collab collab-type="authors">National Institute on Drug Abuse (NIDA)</collab>
. Overdose Death Rates. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates" ext-link-type="uri">https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates</ext-link> (accessed 12 November 2023).</mixed-citation></ref><ref id="add16659-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="add16659-cit-0004"><string-name name-style="western"><surname>Hedegaard</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mini&#241;o</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Spencer</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Warner</surname><given-names>M</given-names></string-name>. <article-title>Drug overdose deaths in the United States, 1999&#8211;2020</article-title>. <source>NCHS Data Brief</source>. <year>2021</year>;<volume>426</volume>:<fpage>1</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">34978529</pub-id></mixed-citation></ref><ref id="add16659-bib-0004"><label>4</label><mixed-citation publication-type="miscellaneous" id="add16659-cit-0005"><collab collab-type="authors">National Institute on Drug Abuse (NIDA)</collab>
. Drug Overdose Death Rates. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates" ext-link-type="uri">https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates</ext-link> (accessed 12 November 2023).</mixed-citation></ref><ref id="add16659-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="add16659-cit-0006"><string-name name-style="western"><surname>Bennett</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Guarino</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Britton</surname><given-names>PC</given-names></string-name>, <string-name name-style="western"><surname>Cook</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>O'Brien&#8208;Mazza</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Taveras</surname><given-names>F</given-names></string-name>, et al. <article-title>Military veterans and the opioid overdose crisis: a review of risk factors and prevention efforts</article-title>. <source>Ann Med</source>. <year>2022</year>;<volume>54</volume>:<fpage>1826</fpage>&#8211;<lpage>1838</lpage>.<pub-id pub-id-type="pmid">35792749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07853890.2022.2092896</pub-id><pub-id pub-id-type="pmcid">PMC9262363</pub-id></mixed-citation></ref><ref id="add16659-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="add16659-cit-0007"><string-name name-style="western"><surname>David</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Sian</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Gebel</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Linas</surname><given-names>BP</given-names></string-name>, <string-name name-style="western"><surname>Samet</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Sprague Martinez</surname><given-names>LS</given-names></string-name>, et al. <article-title>Barriers to accessing treatment for substance use after inpatient managed withdrawal (detox): a qualitative study</article-title>. <source>J Subst Abuse Treat</source>. <year>2022</year>;<volume>142</volume>:<elocation-id>108870</elocation-id>.<pub-id pub-id-type="pmid">36084559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2022.108870</pub-id><pub-id pub-id-type="pmcid">PMC10084712</pub-id></mixed-citation></ref><ref id="add16659-bib-0007"><label>7</label><mixed-citation publication-type="miscellaneous" id="add16659-cit-0008"><collab collab-type="authors">Medicaid and CHIP Payment and Access Commission (MACPAC)</collab>
. <article-title>Report to Congress on Medicaid and CHIP</article-title>. Washington, DC: MACPAC; 2017.</mixed-citation></ref><ref id="add16659-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="add16659-cit-0009"><string-name name-style="western"><surname>Zhang</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Tossone</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ashmead</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bickert</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Bailey</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Doogan</surname><given-names>NJ</given-names></string-name>, et al. <article-title>Examining differences in retention on medication for opioid use disorder: an analysis of Ohio Medicaid data</article-title>. <source>J Subst Abuse Treat</source>. <year>2022</year>;<volume>136</volume>:<elocation-id>108686</elocation-id>.<pub-id pub-id-type="pmid">34953637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2021.108686</pub-id></mixed-citation></ref><ref id="add16659-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="add16659-cit-0010"><string-name name-style="western"><surname>Biondi</surname><given-names>BE</given-names></string-name>, <string-name name-style="western"><surname>Vander Wyk</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Schlossberg</surname><given-names>EF</given-names></string-name>, <string-name name-style="western"><surname>Shaw</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Springer</surname><given-names>SA</given-names></string-name>. <article-title>Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community</article-title>. <source>Addict Sci Clin Pract</source>. <year>2022</year>;<volume>17</volume>:<fpage>15</fpage>.<pub-id pub-id-type="pmid">35255967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13722-022-00299-1</pub-id><pub-id pub-id-type="pmcid">PMC8899775</pub-id></mixed-citation></ref><ref id="add16659-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="add16659-cit-0011"><string-name name-style="western"><surname>Timko</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Schultz</surname><given-names>NR</given-names></string-name>, <string-name name-style="western"><surname>Cucciare</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Vittorio</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Garrison&#8208;Diehn</surname><given-names>C</given-names></string-name>. <article-title>Retention in medication&#8208;assisted treatment for opiate dependence: a systematic review</article-title>. <source>J Addict Dis</source>. <year>2016</year>;<volume>35</volume>:<fpage>22</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">26467975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10550887.2016.1100960</pub-id><pub-id pub-id-type="pmcid">PMC6542472</pub-id></mixed-citation></ref><ref id="add16659-bib-0011"><label>11</label><mixed-citation publication-type="miscellaneous" id="add16659-cit-0012"><collab collab-type="authors">National Quality Forum</collab>
. <article-title>NQF: Behavioral Health 2016&#8211;2017 Final Report</article-title>. <year>2017</year>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.qualityforum.org/Publications/2017/08/Behavioral_Health_2016-2017_Final_Report.aspx" ext-link-type="uri">https://www.qualityforum.org/Publications/2017/08/Behavioral_Health_2016-2017_Final_Report.aspx</ext-link> (accessed 8 October 2019).</mixed-citation></ref><ref id="add16659-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="add16659-cit-0013"><string-name name-style="western"><surname>Williams</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Nunes</surname><given-names>EV</given-names></string-name>, <string-name name-style="western"><surname>Bisaga</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Levin</surname><given-names>FR</given-names></string-name>, <string-name name-style="western"><surname>Olfson</surname><given-names>M</given-names></string-name>. <article-title>Development of a Cascade of care for responding to the opioid epidemic</article-title>. <source>Am J Drug Alcohol Abuse</source>. <year>2019</year>;<volume>45</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1080/00952990.2018.1546862</pub-id><pub-id pub-id-type="pmid">30675818</pub-id><pub-id pub-id-type="pmcid">PMC6404749</pub-id></mixed-citation></ref><ref id="add16659-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="add16659-cit-0014"><string-name name-style="western"><surname>Santo</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hickman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Grebely</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Sordo</surname><given-names>L</given-names></string-name>, et al. <article-title>Association of opioid agonist treatment with all&#8208;cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta&#8208;analysis</article-title>. <source>JAMA Psychiatry</source>. <year>2021</year>;<volume>78</volume>:<fpage>979</fpage>&#8211;<lpage>993</lpage>.<pub-id pub-id-type="pmid">34076676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2021.0976</pub-id><pub-id pub-id-type="pmcid">PMC8173472</pub-id></mixed-citation></ref><ref id="add16659-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="add16659-cit-0015"><string-name name-style="western"><surname>O'Connor</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Cousins</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Durand</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Barry</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Boland</surname><given-names>F</given-names></string-name>. <article-title>Retention of patients in opioid substitution treatment: a systematic review</article-title>. <source>PLoS ONE</source>. <year>2020</year>;<volume>15</volume>:<elocation-id>e0232086</elocation-id>.<pub-id pub-id-type="pmid">32407321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0232086</pub-id><pub-id pub-id-type="pmcid">PMC7224511</pub-id></mixed-citation></ref><ref id="add16659-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="add16659-cit-0016"><string-name name-style="western"><surname>Hser</surname><given-names>YI</given-names></string-name>, <string-name name-style="western"><surname>Saxon</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hasson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hillhouse</surname><given-names>M</given-names></string-name>, et al. <article-title>Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi&#8208;site trial</article-title>. <source>Addiction</source>. <year>2014</year>;<volume>109</volume>:<fpage>79</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="pmid">23961726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/add.12333</pub-id><pub-id pub-id-type="pmcid">PMC3947022</pub-id></mixed-citation></ref><ref id="add16659-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="add16659-cit-0017"><string-name name-style="western"><surname>Manhapra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Petrakis</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Rosenheck</surname><given-names>R</given-names></string-name>. <article-title>Three&#8208;year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration</article-title>. <source>Am J Addict</source>. <year>2017</year>;<volume>26</volume>:<fpage>572</fpage>&#8211;<lpage>580</lpage>.<pub-id pub-id-type="pmid">28472543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ajad.12553</pub-id></mixed-citation></ref><ref id="add16659-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="add16659-cit-0018"><string-name name-style="western"><surname>Manhapra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Agbese</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Leslie</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Rosenheck</surname><given-names>RA</given-names></string-name>. <article-title>Three&#8208;year retention in buprenorphine treatment for opioid use disorder among privately insured adults</article-title>. <source>Psychiatr Serv</source>. <year>2018</year>;<volume>69</volume>:<fpage>768</fpage>&#8211;<lpage>776</lpage>.<pub-id pub-id-type="pmid">29656707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ps.201700363</pub-id></mixed-citation></ref><ref id="add16659-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="add16659-cit-0019"><string-name name-style="western"><surname>Weinstein</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Iqbal</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Cunningham</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Debates</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Landistratis</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Doggett</surname><given-names>P</given-names></string-name>, et al. <article-title>Retention of patients with multiple vulnerabilities in a federally qualified health center buprenorphine program: Pennsylvania, 2017&#8211;2018</article-title>. <source>Am J Public Health</source>. <year>2020</year>;<volume>110</volume>:<fpage>580</fpage>&#8211;<lpage>586</lpage>.<pub-id pub-id-type="pmid">32078355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2105/AJPH.2019.305525</pub-id><pub-id pub-id-type="pmcid">PMC7067078</pub-id></mixed-citation></ref><ref id="add16659-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="add16659-cit-0020"><string-name name-style="western"><surname>Chan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gean</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Arkhipova&#8208;Jenkins</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Gilbert</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hilgart</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fiordalisi</surname><given-names>C</given-names></string-name>, et al. <article-title>Retention strategies for medications for opioid use disorder in adults: a rapid evidence review</article-title>. <source>J Addict Med</source>. <year>2021</year>;<volume>15</volume>:<fpage>74</fpage>.<pub-id pub-id-type="pmid">32956162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ADM.0000000000000739</pub-id><pub-id pub-id-type="pmcid">PMC7864607</pub-id></mixed-citation></ref><ref id="add16659-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="add16659-cit-0021"><string-name name-style="western"><surname>Dematteis</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Auriacombe</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>D'Agnone</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Somaini</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Szerman</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Littlewood</surname><given-names>R</given-names></string-name>, et al. <article-title>Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus</article-title>. <source>Expert Opin Pharmacother</source>. <year>2017</year>;<volume>18</volume>:<fpage>1987</fpage>&#8211;<lpage>1999</lpage>.<pub-id pub-id-type="pmid">29183228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14656566.2017.1409722</pub-id></mixed-citation></ref><ref id="add16659-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="add16659-cit-0022"><string-name name-style="western"><surname>Hser</surname><given-names>YI</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Weiss</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Saxon</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Carroll</surname><given-names>KM</given-names></string-name>, et al. <article-title>Long&#8208;term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi&#8208;site trial</article-title>. <source>Addiction</source>. <year>2016</year>;<volume>111</volume>:<fpage>695</fpage>&#8211;<lpage>705</lpage>.<pub-id pub-id-type="pmid">26599131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/add.13238</pub-id><pub-id pub-id-type="pmcid">PMC4801718</pub-id></mixed-citation></ref><ref id="add16659-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="add16659-cit-0023"><string-name name-style="western"><surname>Nunes</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Scodes</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Pavlicova</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Novo</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>ANC</given-names></string-name>, et al. <article-title>Sublingual Buprenorphine&#8208;Naloxone Compared with Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment</article-title>. <source>Am J Psychiatry</source>. <year>2021</year>;<volume>178</volume>:<fpage>660</fpage>&#8211;<lpage>671</lpage>.<pub-id pub-id-type="pmid">34170188</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.2020.20060816</pub-id><pub-id pub-id-type="pmcid">PMC11061873</pub-id></mixed-citation></ref><ref id="add16659-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="add16659-cit-0024"><string-name name-style="western"><surname>Wakeman</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Larochelle</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Ameli</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Chaisson</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>McPheeters</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Crown</surname><given-names>WH</given-names></string-name>, et al. <article-title>Comparative effectiveness of different treatment pathways for opioid use disorder</article-title>. <source>JAMA Netw Open</source>. <year>2020</year>;<volume>3</volume>:<fpage>e1920622</fpage>&#8211;e1920622.<pub-id pub-id-type="pmid">32022884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2019.20622</pub-id><pub-id pub-id-type="pmcid">PMC11143463</pub-id></mixed-citation></ref><ref id="add16659-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="add16659-cit-0025"><string-name name-style="western"><surname>Lee</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Friedmann</surname><given-names>PD</given-names></string-name>, <string-name name-style="western"><surname>Kinlock</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Nunes</surname><given-names>EV</given-names></string-name>, <string-name name-style="western"><surname>Boney</surname><given-names>TY</given-names></string-name>, <string-name name-style="western"><surname>Hoskinson</surname><given-names>RA</given-names><suffix>Jr</suffix></string-name>, et al. <article-title>Extended&#8208;release naltrexone to prevent opioid relapse in criminal justice offenders</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>374</volume>:<fpage>1232</fpage>&#8211;<lpage>1242</lpage>.<pub-id pub-id-type="pmid">27028913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1505409</pub-id><pub-id pub-id-type="pmcid">PMC5454800</pub-id></mixed-citation></ref><ref id="add16659-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="add16659-cit-0026"><string-name name-style="western"><surname>Schwartz</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>O'Grady</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Kelly</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Gryczynski</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname><given-names>SG</given-names></string-name>, et al. <article-title>Pharmacotherapy for opioid addiction in community corrections</article-title>. <source>Int Rev Psychiatry</source>. <year>2018</year>;<volume>30</volume>:<fpage>117</fpage>&#8211;<lpage>135</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09540261.2018.1524373</pub-id><pub-id pub-id-type="pmcid">PMC6551322</pub-id><pub-id pub-id-type="pmid">30522370</pub-id></mixed-citation></ref><ref id="add16659-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="add16659-cit-0027"><string-name name-style="western"><surname>Degenhardt</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Macpherson</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Leppan</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Nielsen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zahra</surname><given-names>E</given-names></string-name>, et al. <article-title>Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta&#8208;analysis of randomised and observational studies</article-title>. <source>Lancet Psychiatry</source>. <year>2023</year>;<volume>10</volume>:<fpage>386</fpage>&#8211;<lpage>402</lpage>.<pub-id pub-id-type="pmid">37167985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2215-0366(23)00095-0</pub-id></mixed-citation></ref><ref id="add16659-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="add16659-cit-0028"><string-name name-style="western"><surname>Stotts</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Dodrill</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Kosten</surname><given-names>TR</given-names></string-name>. <article-title>Opioid dependence treatment: options in pharmacotherapy</article-title>. <source>Expert Opin Pharmacother</source>. <year>2009</year>;<volume>10</volume>:<fpage>1727</fpage>&#8211;<lpage>1740</lpage>.<pub-id pub-id-type="pmid">19538000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14656560903037168</pub-id><pub-id pub-id-type="pmcid">PMC2874458</pub-id></mixed-citation></ref><ref id="add16659-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="add16659-cit-0029"><string-name name-style="western"><surname>Poulsen</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Asdell</surname><given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Berrettini</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>McBryan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Rahm</surname><given-names>AK</given-names></string-name>. <article-title>Application of the COM&#8208;B model to patient barriers and facilitators of retention in medication treatment for opioid use disorder in rural northeastern United States: a qualitative study</article-title>. <source>SSM&#8212;Mental Health</source>. <year>2022</year>;<volume>2</volume>:<elocation-id>100151</elocation-id>.<pub-id pub-id-type="pmid">36776723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ssmmh.2022.100151</pub-id><pub-id pub-id-type="pmcid">PMC9912293</pub-id></mixed-citation></ref><ref id="add16659-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="add16659-cit-0030"><string-name name-style="western"><surname>Price</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shea</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Gephart</surname><given-names>S</given-names></string-name>. <article-title>The Veterans Affairs&#8217; corporate data warehouse: uses and implications for nursing research and practice</article-title>. <source>Nurs Adm Q</source>. <year>2015</year>;<volume>39</volume>:<fpage>311</fpage>&#8211;<lpage>318</lpage>.<pub-id pub-id-type="pmid">26340242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/NAQ.0000000000000118</pub-id><pub-id pub-id-type="pmcid">PMC10071958</pub-id></mixed-citation></ref><ref id="add16659-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="add16659-cit-0031"><string-name name-style="western"><surname>Wyse</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>McGinnis</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Edelman</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Manhapra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fiellin</surname><given-names>DA</given-names></string-name>, et al. <article-title>Twelve&#8208;month retention in opioid agonist treatment for opioid use disorder among patients with and without HIV</article-title>. <source>AIDS Behav</source>. <year>2022</year>;<volume>26</volume>:<fpage>975</fpage>&#8211;<lpage>985</lpage>.<pub-id pub-id-type="pmid">34495424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10461-021-03452-0</pub-id><pub-id pub-id-type="pmcid">PMC8840957</pub-id></mixed-citation></ref><ref id="add16659-bib-0031"><label>31</label><mixed-citation publication-type="miscellaneous" id="add16659-cit-0032"><article-title>CTN&#8208;0142: Towards Personalized Medicine in Medication for Opioid Use Disorder (MOUD): Analyses of Veterans Health Administration Data to Delineate Patient Characteristics Associated with Treatment Outcomes and Successful MOUD Discontinuation&#8212;CTN Dissemination Library</article-title>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ctnlibrary.org/protocol/ctn0142/" ext-link-type="uri">https://ctnlibrary.org/protocol/ctn0142/</ext-link> (accessed 14 February 2024).</mixed-citation></ref><ref id="add16659-bib-0032"><label>32</label><mixed-citation publication-type="miscellaneous" id="add16659-cit-0033"><collab collab-type="authors">Towards Personalized Medicine in Medication for Opioid Use Disorder (MOUD)</collab>
. : <article-title>Analyses of Veterans Health Administration Data to Delineate Patient Characteristics Associated with Treatment Outcomes and Successful MOUD Discontinuation|National Institute on Drug Abuse (NIDA)</article-title>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nida.nih.gov/about-nida/organization/cctn/ctn/research-studies/towards-personalized-medicine-in-medication-opioid-use-disorder-moud-analyses-veterans-health" ext-link-type="uri">https://nida.nih.gov/about-nida/organization/cctn/ctn/research-studies/towards-personalized-medicine-in-medication-opioid-use-disorder-moud-analyses-veterans-health</ext-link> (accessed 12 November 2023).</mixed-citation></ref><ref id="add16659-bib-0033"><label>33</label><mixed-citation publication-type="miscellaneous" id="add16659-cit-0034"><article-title>A Guide to Accessing and Understanding Mortality Data in the VA Mortality Data Repository</article-title>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.mentalhealth.va.gov/" ext-link-type="uri">www.mentalhealth.va.gov/</ext-link> (accessed 12 November 2023).</mixed-citation></ref><ref id="add16659-bib-0034"><label>34</label><mixed-citation publication-type="miscellaneous" id="add16659-cit-0035"><article-title>USDA ERS&#8212;Rural&#8211;Urban Commuting Area Codes</article-title>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes/" ext-link-type="uri">https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes/</ext-link> (accessed 2 October 2023).</mixed-citation></ref><ref id="add16659-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="add16659-cit-0036"><string-name name-style="western"><surname>Lehnert</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Wilt</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Flanagan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hallisey</surname><given-names>E</given-names></string-name>. <article-title>Spatial exploration of the CDC's social vulnerability index and heat&#8208;related health outcomes in Georgia</article-title>. <source>Int J Disaster Risk Reduct</source>. <year>2020</year>;<fpage>46</fpage>. <pub-id pub-id-type="doi">10.1016/J.IJDRR.2020.101517</pub-id><pub-id pub-id-type="pmcid">PMC9345528</pub-id><pub-id pub-id-type="pmid">35923219</pub-id></mixed-citation></ref><ref id="add16659-bib-0036"><label>36</label><mixed-citation publication-type="miscellaneous" id="add16659-cit-0037"><article-title>CDC/ATSDR Social Vulnerability Index (SVI)</article-title>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.atsdr.cdc.gov/placeandhealth/svi/index.html" ext-link-type="uri">https://www.atsdr.cdc.gov/placeandhealth/svi/index.html</ext-link> (accessed 23 October 2023).</mixed-citation></ref><ref id="add16659-bib-0037"><label>37</label><mixed-citation publication-type="miscellaneous" id="add16659-cit-0038"><article-title>STROBE: Strengthening the Reporting of Observational Studies in Epidemiology</article-title>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.strobe-statement.org/" ext-link-type="uri">https://www.strobe-statement.org/</ext-link> (accessed 12 November 2023).</mixed-citation></ref><ref id="add16659-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="add16659-cit-0039"><string-name name-style="western"><surname>Lagisetty</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Garpestad</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Larkin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Macleod</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Antoku</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Slat</surname><given-names>S</given-names></string-name>, et al. <article-title>Identifying individuals with opioid use disorder: validity of international classification of diseases diagnostic codes for opioid use, dependence and abuse</article-title>. <source>Drug Alcohol Depend</source>. <year>2021</year>;<fpage>221</fpage>. <pub-id pub-id-type="doi">10.1016/J.DRUGALCDEP.2021.108583</pub-id><pub-id pub-id-type="pmcid">PMC8409339</pub-id><pub-id pub-id-type="pmid">33662670</pub-id></mixed-citation></ref><ref id="add16659-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="add16659-cit-0040"><string-name name-style="western"><surname>Fairley</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Humphreys</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Joyce</surname><given-names>VR</given-names></string-name>, <string-name name-style="western"><surname>Bounthavong</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Trafton</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Combs</surname><given-names>A</given-names></string-name>, et al. <article-title>Cost&#8208;effectiveness of treatments for opioid use disorder</article-title>. <source>JAMA Psychiatry</source>. <year>2021</year>;<volume>78</volume>:<fpage>767</fpage>&#8211;<lpage>777</lpage>.<pub-id pub-id-type="pmid">33787832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2021.0247</pub-id><pub-id pub-id-type="pmcid">PMC8014209</pub-id></mixed-citation></ref><ref id="add16659-bib-0040"><label>40</label><mixed-citation publication-type="miscellaneous" id="add16659-cit-0041"><article-title>Medication&#8208;Assisted Treatment for Opioid Use Disorder (HERC)&#8212;VA Phenomics Library</article-title>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://vhacdwdwhweb100.vha.med.va.gov/phenotype/index.php/Medication-Assisted_Treatment_for_Opioid_Use_Disorder_(HERC" ext-link-type="uri">https://vhacdwdwhweb100.vha.med.va.gov/phenotype/index.php/Medication-Assisted_Treatment_for_Opioid_Use_Disorder_(HERC</ext-link>) (accessed 12 November 2023).</mixed-citation></ref><ref id="add16659-bib-0041"><label>41</label><mixed-citation publication-type="miscellaneous" id="add16659-cit-0042">project&#8208;res&#8208;opioid/_104&#8208;pull&#8208;mat&#8208;20221006.sql <article-title>at main &#183; vilijajoyce/project&#8208;res&#8208;opioid &#183; GitHub</article-title>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/vilijajoyce/project-res-opioid/blob/main/_104-pull-mat-20221006.sql" ext-link-type="uri">https://github.com/vilijajoyce/project-res-opioid/blob/main/_104-pull-mat-20221006.sql</ext-link> (accessed 12 November 2023).</mixed-citation></ref><ref id="add16659-bib-0042"><label>42</label><mixed-citation publication-type="miscellaneous" id="add16659-cit-0043"><article-title>Optimizing retention, duration, and discontinuation strategies for opioid use disorder pharmacotherapy (NIH HEAL initiative)|National Institute on Drug Abuse (NIDA)</article-title>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nida.nih.gov/about-nida/organization/cctn/ctn/research-studies/optimizing-retention-duration-discontinuation-strategies-opioid-use-disorder-pharmacotherapy-nih" ext-link-type="uri">https://nida.nih.gov/about-nida/organization/cctn/ctn/research-studies/optimizing-retention-duration-discontinuation-strategies-opioid-use-disorder-pharmacotherapy-nih</ext-link> (accessed 12 November 2023).</mixed-citation></ref><ref id="add16659-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="add16659-cit-0044"><string-name name-style="western"><surname>Williams</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Samples</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Crystal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Olfson</surname><given-names>M</given-names></string-name>. <article-title>Acute care, prescription opioid use, and overdose following discontinuation of long&#8208;term buprenorphine treatment for opioid use disorder</article-title>. <source>Am J Psychiatry</source>. <year>2019</year>;<volume>177</volume>:<fpage>117</fpage>&#8211;<lpage>124</lpage>.<pub-id pub-id-type="pmid">31786933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.2019.19060612</pub-id><pub-id pub-id-type="pmcid">PMC7002204</pub-id></mixed-citation></ref><ref id="add16659-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="add16659-cit-0045"><string-name name-style="western"><surname>Charlson</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Charlson</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Peterson</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Marinopoulos</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Briggs</surname><given-names>WM</given-names></string-name>, <string-name name-style="western"><surname>Hollenberg</surname><given-names>JP</given-names></string-name>. <article-title>The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients</article-title>. <source>J Clin Epidemiol</source>. <year>2008</year>;<volume>61</volume>:<fpage>1234</fpage>&#8211;<lpage>1240</lpage>.<pub-id pub-id-type="pmid">18619805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinepi.2008.01.006</pub-id></mixed-citation></ref><ref id="add16659-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="add16659-cit-0046"><string-name name-style="western"><surname>Cacciola</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Alterman</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>DePhilippis</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Drapkin</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Valadez</surname><given-names>C</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Fala</surname><given-names>NC</given-names></string-name>, et al. <article-title>Development and initial evaluation of the brief addiction monitor (BAM)</article-title>. <source>J Subst Abuse Treat</source>. <year>2013</year>;<volume>44</volume>:<fpage>256</fpage>&#8211;<lpage>263</lpage>.<pub-id pub-id-type="pmid">22898042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2012.07.013</pub-id><pub-id pub-id-type="pmcid">PMC3602977</pub-id></mixed-citation></ref><ref id="add16659-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="add16659-cit-0047"><string-name name-style="western"><surname>O'Donnell</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gladden</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Mattson</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Hunter</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>NL</given-names></string-name>. <article-title>Vital signs: characteristics of drug overdose deaths involving opioids and stimulants&#8212;24 states and the District of Columbia, January&#8211;June 2019</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2020</year>;<volume>69</volume>:<fpage>1189</fpage>&#8211;<lpage>1197</lpage>.<pub-id pub-id-type="pmid">32881854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6935a1</pub-id><pub-id pub-id-type="pmcid">PMC7470457</pub-id></mixed-citation></ref><ref id="add16659-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="add16659-cit-0048"><string-name name-style="western"><surname>Weiner</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>el Ibrahimi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hendricks</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Hallvik</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Hildebran</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fischer</surname><given-names>MA</given-names></string-name>, et al. <article-title>Factors associated with opioid overdose after an initial opioid prescription</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>:<elocation-id>e2145691</elocation-id>.<pub-id pub-id-type="pmid">35089351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.45691</pub-id><pub-id pub-id-type="pmcid">PMC8800077</pub-id></mixed-citation></ref><ref id="add16659-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="add16659-cit-0049"><string-name name-style="western"><surname>Lyons</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Yule</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Schiff</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bagley</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Wilens</surname><given-names>TE</given-names></string-name>. <article-title>Risk factors for drug overdose in young people: a systematic review of the literature</article-title>. <source>J Child Adolesc Psychopharmacol</source>. <year>2019</year>;<volume>29</volume>:<fpage>487</fpage>&#8211;<lpage>497</lpage>.<pub-id pub-id-type="pmid">31246496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/cap.2019.0013</pub-id><pub-id pub-id-type="pmcid">PMC6727478</pub-id></mixed-citation></ref><ref id="add16659-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="add16659-cit-0050"><string-name name-style="western"><surname>Duca</surname><given-names>JV</given-names></string-name>, <string-name name-style="western"><surname>Rosenthal</surname><given-names>SS</given-names></string-name>. <article-title>Borrowing constraints and access to owner&#8208;occupied housing</article-title>. <source>Reg Sci Urban Econ</source>. <year>1994</year>;<volume>24</volume>:<fpage>301</fpage>&#8211;<lpage>322</lpage>.</mixed-citation></ref><ref id="add16659-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="add16659-cit-0051"><string-name name-style="western"><surname>Alford</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>LaBelle</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Kretsch</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bergeron</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Winter</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Botticelli</surname><given-names>M</given-names></string-name>, et al. <article-title>Collaborative care of opioid&#8208;addicted patients in primary care using buprenorphine</article-title>. <source>Arch Intern Med</source>. <year>2011</year>;<volume>171</volume>:<fpage>425</fpage>&#8211;<lpage>431</lpage>.<pub-id pub-id-type="pmid">21403039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archinternmed.2010.541</pub-id><pub-id pub-id-type="pmcid">PMC3059544</pub-id></mixed-citation></ref><ref id="add16659-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="add16659-cit-0052"><string-name name-style="western"><surname>Cousins</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Radfar</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Cr&#232;vecoeur&#8208;MacPhail</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ang</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Darfler</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Rawson</surname><given-names>RA</given-names></string-name>. <article-title>Predictors of continued use of extended&#8208;released naltrexone (XR&#8208;NTX) for opioid&#8208;dependence: an analysis of heroin and non&#8208;heroin opioid users in Los Angeles County</article-title>. <source>J Subst Abuse Treat</source>. <year>2016</year>;<volume>63</volume>:<fpage>66</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">26823295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2015.12.004</pub-id></mixed-citation></ref><ref id="add16659-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="add16659-cit-0053"><string-name name-style="western"><surname>Sullivan</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Rothenberg</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Vosburg</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Church</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Feldman</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Epstein</surname><given-names>EM</given-names></string-name>, et al. <article-title>Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial</article-title>. <source>Am J Addict</source>. <year>2006</year>;<volume>15</volume>:<fpage>150</fpage>&#8211;<lpage>159</lpage>.<pub-id pub-id-type="pmid">16595353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10550490500528464</pub-id></mixed-citation></ref><ref id="add16659-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="add16659-cit-0054"><string-name name-style="western"><surname>Finlay</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Harris</surname><given-names>AHS</given-names></string-name>, <string-name name-style="western"><surname>Timko</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Smelson</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Stimmel</surname><given-names>M</given-names></string-name>, et al. <article-title>Disparities in access to medications for opioid use disorder in the Veterans Health Administration</article-title>. <source>J Addict Med</source>. <year>2021</year>;<volume>15</volume>:<fpage>143</fpage>&#8211;<lpage>149</lpage>.<pub-id pub-id-type="pmid">32826617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ADM.0000000000000719</pub-id><pub-id pub-id-type="pmcid">PMC7889740</pub-id></mixed-citation></ref><ref id="add16659-bib-0054"><label>54</label><mixed-citation publication-type="miscellaneous" id="add16659-cit-0055"><collab collab-type="authors">VA Priority Groups</collab>
. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://veteran.com/va-priority-groups/" ext-link-type="uri">https://veteran.com/va-priority-groups/</ext-link> (accessed 27 November 2023).</mixed-citation></ref><ref id="add16659-bib-0055"><label>55</label><mixed-citation publication-type="miscellaneous" id="add16659-cit-0056"><collab collab-type="authors">WWAMI Rural Health Research Center</collab>
. <article-title>Rural&#8211;urban commuting area codes data</article-title>. <year>2005</year>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://depts.washington.edu/uwruca/ruca-uses.php" ext-link-type="uri">http://depts.washington.edu/uwruca/ruca-uses.php</ext-link> (accessed 5 December 2017).</mixed-citation></ref><ref id="add16659-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="add16659-cit-0057"><string-name name-style="western"><surname>Quan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sundararajan</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Halfon</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Fong</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Burnand</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Luthi</surname><given-names>JC</given-names></string-name>, et al. <article-title>Coding algorithms for defining comorbidities in ICD&#8208;9&#8208;CM and ICD&#8208;10 administrative data</article-title>. <source>Med Care</source>. <year>2005</year>;<volume>43</volume>:<fpage>1130</fpage>&#8211;<lpage>1139</lpage>. <pub-id pub-id-type="doi">10.1097/01.mlr.0000182534.19832.83</pub-id><pub-id pub-id-type="pmid">16224307</pub-id></mixed-citation></ref><ref id="add16659-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="add16659-cit-0058"><string-name name-style="western"><surname>Kaplan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Venezky</surname><given-names>RL</given-names></string-name>. <article-title>Literacy and voting behavior: a bivariate probit model with sample selection</article-title>. <source>Soc Sci Res</source>. <year>1994</year>;<volume>23</volume>:<fpage>350</fpage>&#8211;<lpage>367</lpage>.</mixed-citation></ref><ref id="add16659-bib-0058"><label>58</label><mixed-citation publication-type="book" id="add16659-cit-0059"><string-name name-style="western"><surname>Cameron</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Trivedi</surname><given-names>PK</given-names></string-name>. <source>Microeconometrics: Methods and Applications</source><edition designator="1">1st ed.</edition><publisher-loc>Cambridge, UK</publisher-loc>: <publisher-name>Cambridge University Press</publisher-name>; <year>2005</year>.</mixed-citation></ref><ref id="add16659-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="add16659-cit-0060"><string-name name-style="western"><surname>Fiellin</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Schottenfeld</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Cutter</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Moore</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Barry</surname><given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>O'Connor</surname><given-names>PG</given-names></string-name>. <article-title>Primary care&#8208;based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial</article-title>. <source>JAMA Intern Med</source>. <year>2014</year>;<volume>174</volume>:<fpage>1947</fpage>&#8211;<lpage>1954</lpage>.<pub-id pub-id-type="pmid">25330017</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2014.5302</pub-id><pub-id pub-id-type="pmcid">PMC6167926</pub-id></mixed-citation></ref><ref id="add16659-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="add16659-cit-0061"><string-name name-style="western"><surname>Sordo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Barrio</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bravo</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Indave</surname><given-names>BI</given-names></string-name>, <string-name name-style="western"><surname>Degenhardt</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wiessing</surname><given-names>L</given-names></string-name>, et al. <article-title>Mortality risk during and after opioid substitution treatment: systematic review and meta&#8208;analysis of cohort studies</article-title>. <source>BMJ</source>. <year>2017</year>;<volume>357</volume>:<elocation-id>j1550</elocation-id>.<pub-id pub-id-type="pmid">28446428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.j1550</pub-id><pub-id pub-id-type="pmcid">PMC5421454</pub-id></mixed-citation></ref><ref id="add16659-bib-0061"><label>61</label><mixed-citation publication-type="miscellaneous" id="add16659-cit-0062"><collab collab-type="authors">The SCOUTT Initiative</collab>
. <article-title>Increasing Medication Treatment for Veterans with Opioid Use Disorder</article-title>. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.queri.research.va.gov/qnews/oct22/default.cfm?QnewsMenu=article1" ext-link-type="uri">https://www.queri.research.va.gov/qnews/oct22/default.cfm?QnewsMenu=article1</ext-link> (accessed 18 April 2024).</mixed-citation></ref><ref id="add16659-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="add16659-cit-0063"><string-name name-style="western"><surname>Larochelle</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Bernson</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Land</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Stopka</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Xuan</surname><given-names>Z</given-names></string-name>, et al. <article-title>Medication for opioid use disorder after nonfatal opioid overdose and association with mortality</article-title>. <source>Ann Intern Med</source>. <year>2018</year>;<volume>169</volume>:<fpage>137</fpage>&#8211;<lpage>145</lpage>.<pub-id pub-id-type="pmid">29913516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M17-3107</pub-id><pub-id pub-id-type="pmcid">PMC6387681</pub-id></mixed-citation></ref><ref id="add16659-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="add16659-cit-0064"><string-name name-style="western"><surname>Lee</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Nunes EV Jr</surname></string-name>, <string-name name-style="western"><surname>Novo</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bachrach</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bailey</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Bhatt</surname><given-names>S</given-names></string-name>, et al. <article-title>Comparative effectiveness of extended&#8208;release naltrexone versus buprenorphine&#8208;naloxone for opioid relapse prevention (X:BOT): a multicentre, open&#8208;label, randomised controlled trial</article-title>. <source>Lancet</source>. <year>2018</year>;<volume>391</volume>:<fpage>309</fpage>&#8211;<lpage>318</lpage>.<pub-id pub-id-type="pmid">29150198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(17)32812-X</pub-id><pub-id pub-id-type="pmcid">PMC5806119</pub-id></mixed-citation></ref><ref id="add16659-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="add16659-cit-0065"><string-name name-style="western"><surname>Stafford</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Marrero</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Naumann</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Lich</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Wakeman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jalali</surname><given-names>MS</given-names></string-name>. <article-title>Identifying key risk factors for premature discontinuation of opioid use disorder treatment in the United States: a predictive modeling study</article-title>. <source>Drug Alcohol Depend</source>. <year>2022</year>;<volume>237</volume>:<elocation-id>109507</elocation-id>.<pub-id pub-id-type="pmid">35660221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2022.109507</pub-id></mixed-citation></ref><ref id="add16659-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="add16659-cit-0066"><string-name name-style="western"><surname>Weinstein</surname><given-names>ZM</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>HW</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Quinn</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Hui</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Labelle</surname><given-names>CT</given-names></string-name>, et al. <article-title>Long&#8208;term retention in office based opioid treatment with buprenorphine</article-title>. <source>J Subst Abuse Treat</source>. <year>2017</year>;<volume>74</volume>:<fpage>65</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="pmid">28132702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2016.12.010</pub-id><pub-id pub-id-type="pmcid">PMC5312773</pub-id></mixed-citation></ref><ref id="add16659-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="add16659-cit-0067"><string-name name-style="western"><surname>Mintz</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Presnall</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>KY</given-names></string-name>, <string-name name-style="western"><surname>Hartz</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Sahrmann</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Bierut</surname><given-names>LJ</given-names></string-name>, et al. <article-title>An examination between treatment type and treatment retention in persons with opioid and co&#8208;occurring alcohol use disorders</article-title>. <source>Drug Alcohol Depend</source>. <year>2021</year>;<volume>226</volume>:<elocation-id>108886</elocation-id>.<pub-id pub-id-type="pmid">34245997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2021.108886</pub-id><pub-id pub-id-type="pmcid">PMC8370094</pub-id></mixed-citation></ref><ref id="add16659-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="add16659-cit-0068"><string-name name-style="western"><surname>Landis</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Levin</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Saloner</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Dick</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Sherry</surname><given-names>TB</given-names></string-name>, et al. <article-title>Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine</article-title>. <source>Subst Abuse</source>. <year>2022</year>;<volume>43</volume>:<fpage>1057</fpage>&#8211;<lpage>1071</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08897077.2022.2060424</pub-id><pub-id pub-id-type="pmcid">PMC9945372</pub-id><pub-id pub-id-type="pmid">35442178</pub-id></mixed-citation></ref><ref id="add16659-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="add16659-cit-0069"><string-name name-style="western"><surname>Chambers</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Hllowell</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Zullo</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Paiva</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Berk</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gaither</surname><given-names>R</given-names></string-name>, et al. <article-title>Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl</article-title>. <source>JAMA Netw Open</source>. <year>2023</year>;<volume>6</volume>:<elocation-id>e2334540</elocation-id>.<pub-id pub-id-type="pmid">37721749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2023.34540</pub-id><pub-id pub-id-type="pmcid">PMC10507490</pub-id></mixed-citation></ref><ref id="add16659-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="add16659-cit-0070"><string-name name-style="western"><surname>Hochheimer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Unick</surname><given-names>GJ</given-names></string-name>. <article-title>Systematic review and meta&#8208;analysis of retention in treatment using medications for opioid use disorder by medication, race/ethnicity, and gender in the United States</article-title>. <source>Addict Behav</source>. <year>2022</year>;<volume>124</volume>:<elocation-id>107113</elocation-id>.<pub-id pub-id-type="pmid">34543869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addbeh.2021.107113</pub-id></mixed-citation></ref><ref id="add16659-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="add16659-cit-0071"><string-name name-style="western"><surname>Friedman</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname><given-names>H</given-names></string-name>. <article-title>Evaluation of increases in drug overdose mortality rates in the US by race and ethnicity before and during the COVID&#8208;19 pandemic</article-title>. <source>JAMA Psychiatry</source>. <year>2022</year>;<volume>79</volume>:<fpage>379</fpage>&#8211;<lpage>381</lpage>.<pub-id pub-id-type="pmid">35234815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2022.0004</pub-id><pub-id pub-id-type="pmcid">PMC8892360</pub-id></mixed-citation></ref><ref id="add16659-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="add16659-cit-0072"><string-name name-style="western"><surname>Han</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Einstein</surname><given-names>EB</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Cotto</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Compton</surname><given-names>WM</given-names></string-name>, <string-name name-style="western"><surname>Volkow</surname><given-names>ND</given-names></string-name>. <article-title>Racial and ethnic disparities in drug overdose deaths in the US during the COVID&#8208;19 pandemic</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>:<elocation-id>e2232314</elocation-id>.<pub-id pub-id-type="pmid">36125815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.32314</pub-id><pub-id pub-id-type="pmcid">PMC9490498</pub-id></mixed-citation></ref><ref id="add16659-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="add16659-cit-0073"><string-name name-style="western"><surname>Nalven</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Spillane</surname><given-names>NS</given-names></string-name>, <string-name name-style="western"><surname>Schick</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Weyandt</surname><given-names>LL</given-names></string-name>. <article-title>Diversity inclusion in United States opioid pharmacological treatment trials: a systematic review</article-title>. <source>Exp Clin Psychopharmacol</source>. <year>2021</year>;<volume>29</volume>:<fpage>524</fpage>&#8211;<lpage>538</lpage>.<pub-id pub-id-type="pmid">34242040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/pha0000510</pub-id><pub-id pub-id-type="pmcid">PMC8511246</pub-id></mixed-citation></ref><ref id="add16659-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="add16659-cit-0074"><string-name name-style="western"><surname>Krawczyk</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Saloner</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Cerd&#225;</surname><given-names>M</given-names></string-name>. <article-title>Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings</article-title>. <source>J Subst Abuse Treat</source>. <year>2021</year>;<volume>126</volume>:<elocation-id>108329</elocation-id>.<pub-id pub-id-type="pmid">34116820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2021.108329</pub-id><pub-id pub-id-type="pmcid">PMC8197774</pub-id></mixed-citation></ref><ref id="add16659-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="add16659-cit-0075"><string-name name-style="western"><surname>Gomes</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>McCormack</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bozinoff</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Tadrous</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Antoniou</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Munro</surname><given-names>C</given-names></string-name>, et al. <article-title>Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population&#8208;based propensity&#8208;score matched cohort study</article-title>. <source>Addiction</source>. <year>2022</year>;<volume>117</volume>:<fpage>1972</fpage>&#8211;<lpage>1981</lpage>.<pub-id pub-id-type="pmid">35257434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/add.15862</pub-id><pub-id pub-id-type="pmcid">PMC9313829</pub-id></mixed-citation></ref><ref id="add16659-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="add16659-cit-0076"><string-name name-style="western"><surname>Ruhm</surname><given-names>CJ</given-names></string-name>. <article-title>Corrected US opioid&#8208;involved drug poisoning deaths and mortality rates, 1999&#8211;2015</article-title>. <source>Addiction</source>. <year>2018</year>;<volume>113</volume>:<fpage>1339</fpage>&#8211;<lpage>1344</lpage>.<pub-id pub-id-type="pmid">29430760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/add.14144</pub-id></mixed-citation></ref><ref id="add16659-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="add16659-cit-0077"><string-name name-style="western"><surname>Riggs</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>DeRussy</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Leisch</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shover</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Bohnert</surname><given-names>ASB</given-names></string-name>, <string-name name-style="western"><surname>Hoge</surname><given-names>AE</given-names></string-name>, et al. <article-title>Sensitivity of health records for self&#8208;reported nonfatal drug and alcohol overdose</article-title>. <source>Am J Addict</source>. <year>2022</year>;<volume>31</volume>:<fpage>517</fpage>&#8211;<lpage>522</lpage>.<pub-id pub-id-type="pmid">36000282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ajad.13327</pub-id><pub-id pub-id-type="pmcid">PMC9617764</pub-id></mixed-citation></ref><ref id="add16659-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="add16659-cit-0078"><string-name name-style="western"><surname>Luo</surname><given-names>SX</given-names></string-name>, <string-name name-style="western"><surname>Feaster</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Balise</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Bouzoubaa</surname><given-names>L</given-names></string-name>, et al. <article-title>Individual&#8208;level risk prediction of return to use during opioid use disorder treatment</article-title>. <source>JAMA Psychiatry</source>. <year>2024</year>;<volume>81</volume>:<fpage>45</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">37792357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2023.3596</pub-id><pub-id pub-id-type="pmcid">PMC10551817</pub-id></mixed-citation></ref><ref id="add16659-bib-0078"><label>78</label><mixed-citation publication-type="miscellaneous" id="add16659-cit-0079"><string-name name-style="western"><surname>Spencer</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Warner</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cisewski</surname><given-names>JA</given-names></string-name>, et al. <article-title>Estimates of Drug Overdose Deaths involving Fentanyl, Methamphetamine, Cocaine, Heroin, and Oxycodone</article-title>: United States, 2021. Vital Statistics Rapid Release no. 27. Hyattsville, MD: National Center for Health Statistics <year>2023</year>. <pub-id pub-id-type="doi">10.15620/CDC:125504</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>